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Cancer is an exceptionally complex disease which requires an appropriately sophisticated 
model to facilitate its research. Organoids are 3D structures generated from stem cells, which 
recapitulate a target organ. These spherical cell cultures have the delicate organisation of the 
in vivo tissue, albeit on a smaller, simpler scale. Organoids are emerging in the field as 
invaluable tools for studying normal organogenesis and disease. Additionally, they can be used 
as an intermediate step between 2D cell lines and animal models in drug screens. This project 
describes the establishment and characterisation of mouse-derived gastric organoids as a 
disease model and medium-throughput drug screening tool for E-cadherin negative (CDH1-/-) 
hereditary diffuse gastric cancer (HDGC). Their primary use will be to identify drugs that can 
be used as chemopreventative treatments for HDGC. 
 
Organoids were cultured using an air-liquid interface (ALI) method from the gastric stem cells 
of conditional Cdh1 knockout mice. Cdh1 deletion was induced by co-culturing with 
endoxifen. Immunofluorescence and confocal microscopy have been used in the 
characterisation of the organoids and to validate the efficacy of Cdh1 knockout. For drug 
screening, organoids were first exposed to the drug 48h post-seeding, and effects were recorded 
at 24 h intervals for 96 h.  
 
Our gastric organoids harbour functional populations of epithelial cells and proliferating stem 
cells. They are spherical and cystic in shape, containing an inner lumen surrounded by 
epithelium. Cdh1-negative cells accumulate in the lumen of the organoids, possibly due to their 
impaired cell-cell adhesion ability relative to the Cdh1-positive cells. ARQ-092 and MK2206, 
both pan-AKT inhibitors, have been shown to reduce growth and induce death in the organoids 
in a synthetic lethal manner, validating their use as a drug screening tool for the development 
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Gastric cancer, encompassing both intestinal and diffuse subtypes, is the fourth most common 
cancer worldwide and the second leading cause of cancer-related deaths (Nadauld & Ford, 
2013). Rates of gastric cancer vary drastically between countries, but are generally highest in 
Eastern Asia and lowest in North America and Africa (Torre et al., 2015). This geographical 
variation can be largely attributed to regional differences in diet, food storage and rates of 
Helicobacter Pylori infection (Parkin, 2006). Despite ongoing clinical and scientific research, 
gastric cancer persists as a highly prevalent disease with a generally poor prognosis. Treatment 
advancement is relatively slow, due to a lack of understanding surrounding the exact molecular 
changes that underpin the development of the disease, resulting in a poor 5-year survival rate 
of under 25% (Ferlay et al., 2010). Part of the difficulty in understanding and treating gastric 
cancer is that it is a multifactorial disease, with many genetic and environmental risk factors 
contributing to its carcinogenesis.  
 
1.1.2 Subtypes  
 
The two histologically distinct gastric cancer subtypes as defined by the Lauren classification  
(Lauren, 1965), intestinal and diffuse, differ in their primary risk factors as well as their 
morphology, epidemiology and molecular mechanisms of development (Nadauld & Ford, 
2013). Intestinal-type gastric cancer is more prevalent as an aging disease, has stronger links 
to environmental risk factors and a more differentiated phenotype, while diffuse-type generally 
has a younger age of onset, inherited risk factors, and a diffuse phenotype (Poultsides & 
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Norton, 2015). Diffuse-type is the less common form of the two subtypes, accounting for 
approximately 30% of all gastric cancer cases (Oliveira et al., 2009). 
 
1.1.3 Stomach anatomy  
 
 
Figure 1.1 | Organisation of gastric glands. A) Each gland is divided into four regions: the 
pit, isthmus, gland neck and gland base. Stem cells reside in the isthmus and gland base, where 
they divide and differentiate, renewing the various cell types of the gland. Adapted from 
Pompaiah & Bartfield, 2017.  
 
Mutations that cause dysregulation of the stem cell population within the gastric gland are often 
at the root of gastric cancer. The inner stomach wall is lined by columnar epithelial cells, 
organised into deep crater-like indentations called gastric pits (Fig. 1.1). Each gastric gland 
acts like a conveyer belt; a production line of various differentiated cells, all being generated 
from a meticulously regulated population of stem cells within the gland. The turnover of cells 
in the gastric gland is both continuous and tightly regulated. Each cell type is renewed at a 
different rate, ranging from 3 days to 6 months (Pompaiah & Bartfeld, 2017). Moreover, the 
turnover rate within each cell type is dynamic, gaining or losing speed depending on the needs 
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of the gastric environment at any given time. This enormous regenerative burden sits on the 
shoulders of the small stem cell population harboured within the gastric pits. When this tightly 
regulated system malfunctions, the effects are substantial and widespread.  
 
1.2 Hereditary Diffuse Gastric Cancer 
 
1.2.1 Introduction  
 
Although the vast majority of both intestinal- and diffuse-type gastric cancers are sporadic, a 
few percent of diffuse-type cases are caused by an autosomal dominant gastric cancer 
predisposition syndrome called Hereditary Diffuse Gastric Cancer (HDGC) (Fitzgerald et al., 
2010; Guilford et al., 1998). HDGC has been genetically defined by the presence of an 
inactivating, germline mutation in the tumour suppressor gene CDH1 (Guilford et al., 1999), 
although occasional mutations in other genes with related function, such as CTNNA1, have 
been reported (Hansford et al., 2015).   
 
The clinical criteria to trigger mutation screening in gastric cancer cases is currently as follows:  
- Families where two or more members develop gastric cancer (one diffuse type) at any 
age. 
- Anyone who presents with diffuse gastric cancer (DGC) before the age of 40. 
- Families with at least one case of both DGC and lobular breast cancer (LBC), one 
before the age of 50. 
Screening could also be considered in patients presenting with bilateral or familial LBC before 
the age of 50, patients with precursor signet ring cell carcinoma lesions and patients presenting 
with DGC who also have a cleft lip/palate (van der Post et al., 2015).  
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Overall, New Zealand has a relatively low incidence of gastric cancer. However, the New 
Zealand Māori population, which comprises 15% of the total population, harbours rates of 
gastric cancer more than three times higher than that of the non-Māori population (Ministry of 
Health, 2015). In further contrast to the general population, the predominant subtype being 
presented within Māori is diffuse, and the age of onset is on average 10 years younger than that 
of non-Māori. It has recently been reported that this disproportionately high prevalence can be 
partly attributed to the  increased frequency of germline mutations in the CDH1 gene in New 
Zealand Māori (Hakkaart et al., 2018). 
 
1.2.2 CDH1 Function 
 
The CDH1 gene is located on chromosome 16q22.1 and spans over 100 kB. It has a 2.6 kb 
coding sequence, which is divided into 16 exons (Dunbier & Guilford, 2001). The protein 
product of CDH1, Epithelial cadherin (E-cadherin), is a type I cadherin, and the founding 
member of the cadherin superfamily. E-cadherin’s primary role in the body is to act as an 
adhesive protein between cells in epithelial tissue. First cloned and fully characterised in 1995, 
E-cadherin is defined as a calcium-dependent epithelial cell-cell adhesion glycoprotein (Berx 
et al., 1995). It has an extracellular domain for intercellular adhesion, a single-pass 
transmembrane region and a highly conserved intracellular domain (Grunwald, 1993; Takeichi, 
1991). The extracellular domain forms homophilic bonds with E-cadherin molecules on 
neighbouring cells, while the cytoplasmic domain interacts with the actin cytoskeleton via 
catenins, along with other transmembrane and cytoplasmic proteins (Brieher & Yap, 2013; 
Kemler, 1993). The inter- and intracellular interactions that E-cadherin forms are the core of 
adherens junctions – strong, dynamic links between neighbouring cells.  
 
In addition to its role in cell adhesion and cytoskeletal organisation, E-cadherin also acts to 
transduce mechanical stress across the cell membrane and trigger intracellular signalling 
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cascades, initiating many integral growth, proliferation and survival pathways (Berx et al., 
1995; Lecuit & Yap, 2015). Furthermore, it plays a crucial role in the contact inhibition of cell 
growth and programmed cell death. Epithelial cells continually proliferate until they have 
occupied a defined area – a process that is especially active during embryogenesis and wound 
healing. Once the defined area has been sufficiently occupied with epithelial tissue, growth 
signals are repressed and proliferation pathways are inhibited, halting growth (Kim, Koh, Chen, 
& Gumbiner, 2011). This contact inhibition of cells, along with controlled cell death, is crucial 
to the maintenance and correct function of complex tissues and is the basis of E-cadherin’s 
classification as a tumour suppressor. 
 
1.2.3 CDH1’s Role in Cancer 
 
E-cadherin’s role as a tumour suppressor gene means that silencing mutations and 
downregulation of E-cadherin expression can result in cells displaying poor differentiation, 
strong invasive potential, loss of polarity and mesenchymal phenotypes (Berx et al., 1995; P. 
Carneiro et al., 2012; Menke & Giehl, 2012). For these reasons, it is often correlated with poor 
prognosis in various epithelial cancers. E-cadherin promotor studies have shown negative 
regulation throughout tumour progression, further affirming the inverse relationship between 
the normal expression of E-cadherin and human malignancy (Berx et al., 1995). Notably, 
somatic mutations in the E-cadherin gene have been strongly linked with sporadic diffuse-type 
gastric cancers and lobular breast cancer (Dunbier & Guilford, 2001).   
 
1.2.4 CDH1’s Role in HDGC 
 
Those born with a heterozygous inactivating mutation in CDH1 have a 70% chance of 
developing DGC in their lifetime, as well as an additional 40% chance of LBC (Hansford et 
al., 2015; van der Post et al., 2015). In 1998, CDH1 was identified as the primary gene 
responsible for HDGC. Genetic linkage analysis and sequencing were used to identify 
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inactivating CDH1 mutations in three Māori families harbouring high rates of diffuse gastric 
cancer (Guilford et al., 1998). Age of onset for diffuse gastric cancer in these families was 
exceptionally low. The majority of those with clinically apparent stomach cancer were under 
40, with the youngest patient dying at only 14 years of age (Guilford et al., 1998).  
 
Although there are no dominant mutational hotspots in CDH1, over 155 germline mutations 
have been identified in different HDGC families (Hansford et al., 2015), and it is estimated 
that there are now over 500 known HDGC families worldwide (P. Guilford, pers. comm.). 
There is no known correlation between the type and location of CDH1 mutation and cancer 
phenotype (Guilford, Humar, & Blair, 2010).  
 
1.2.5 Onset  
 
It is a heterozygous inactivation of CDH1 that predisposes mutation carriers in HDGC families 
to developing DGC; homozygous loss of CDH1 is embryonically lethal (Guilford et al., 2010). 
Cells that develop into HDGC-related cancers have undergone somatic inactivation of the 
second copy of CDH1, which can happen at any point throughout the mutation carrier’s life. It 
is thought that this inactivation occurs largely through epigenetic mechanisms, including DNA 
promoter hypermethylation. Cells with a homozygous loss of CDH1 are devoid of E-cadherin, 
and therefore have disrupted cellular function in many integral growth, survival and 
proliferation pathways. 
 
After the second copy of CDH1 has been lost, the onset of gastric cancer is typified by the 
development of stage T1a signet ring cell carcinomas (Guilford et al., 2010). These carcinomas 
are initially relatively indolent, displaying lower rates of proliferation than surrounding non-
malignant cells. As many as several hundred T1a foci have been observed in a single patient 




Following the initial development of multifocal T1a signet ring cell carcinomas, a small 
proportion of these cancers progress to higher stage (Guilford, 1999). Lacking the tumour 
supressing function of E-cadherin, these cells adopt an invasive phenotype, where their poorly 
defined cell architecture allows them to infiltrate the underlying stroma. The timing of this 
process is unclear, as evidence suggests that there is an undefined period of dormancy after the 
initial development of a signet ring cell carcinoma (Barber et al., 2008). Once the cancer does 
begin to progress, the process is often rapid. 
 
Cancer progression is often aligned with a transition of the cells into a mesenchymal phenotype 
(Egeblad et al., 2010). This process is known as epithelial to mesenchymal transition (EMT) 
and is a well-established hallmark of cancer advancement. The phenotypic change causes the 
cells to lose polarity, gain migratory and invasive abilities and resist apoptosis. Specifically, 
the down regulation of E-cadherin as a crucial epithelial cell-cell adhesion protein results in b-
catenin being released from its usual membrane-bound position. Free b-catenin is translocated 
to the nucleus where it is responsible for the activation of signalling pathways, such as WNT, 
that promote cell motility and prevent adhesion. This process ultimately provides the cells with 
the ability to metastasise (Egeblad et al., 2010). In cancers such as HDGC where the loss of E-
cadherin plays a causal role, and expression is lost early on in cancer progression, tumours 
display an almost permanent mesenchymal phenotype (Guilford et al., 1998; Yang & 
Weinberg, 2008). 
 
1.2.7 Current clinical management 
 
As it stands, the only treatments available to those born with a CDH1 mutation contain 
significant drawbacks. The clinical management of HDGC begins with genetic counselling and 
predictive testing for mutation(s) in the CDH1 gene from approximately 16 years of age for 
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those in known HDGC families (van der Post et al., 2015). These are typically families who 
have presented with one or more cases of diffuse gastric cancer or lobular breast cancer, 
especially those with early-onset cases. It is also recommended that regardless of family 
history, individuals presenting with DGC below the age of 40 should be screened for germline 
CDH1 mutations (Poultsides & Norton, 2015).  
 
Family members identified as carrying a CDH1 mutation must then consider their treatment 
options, which are outlined below. 
 
1.2.7.1 Surveillance  
 
Patients can opt for a surveillance strategy, where they undergo regular endoscopies and 
biopsies – usually annual – to monitor for the presence of cancerous gastric signet ring cells. 
However, the histological nature of HDGC is diffuse, in that its onset is defined by small, 
unevenly distributed malignant foci which spread below an intact mucosa and are therefore 
difficult to detect. Moreover, the number of these foci can vary significantly between individual 
patients. In a study of six patients from three HDGC kindred in New Zealand, the number of 
foci in each individual stomach ranged between 4-318 (Charlton et al., 2004). In another study 
of nine HDGC cases, gastrectomy specimens contained between one and 161 individual foci, 
many of which were underlying the normal mucosa (Carneiro et al., 2004). For these reasons, 
the surveillance strategy, though beneficial in its relatively low-impact nature, is imperfect. 
Even with rigorous check-ups, the early-stage signet ring cells can be missed by endoscopy. 
This has been reported in multiple case studies, where patients receive negative biopsy results 
despite having extensive DGC (Huntsman et al., 2001). If advanced disease is missed, the 
patient’s prognosis is generally poor. By the time the cancer has become clinically apparent, 
the 5 year survival rate is a dismal 10% (Poultsides & Norton, 2015).  For these reasons, it is 
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recommended that individuals who test positive for a CDH1 mutation, regardless of endoscopic 
findings, should consider a prophylactic gastrectomy (Fitzgerald et al., 2010). 
   
1.2.7.2 Prophylactic gastrectomy 
 
The second treatment option, though more effective than the former, is not without its own 
caveats. Due to the wide distribution of signet ring cells throughout the stomach, the only sure 
way of eliminating all risk of HDGC is to surgically remove the entire stomach. Patients can 
therefore opt for a gastrectomy. Although preferable to gastric cancer, this procedure can have 
a long-term detrimental impact on the patient’s quality of life. It is a technical procedure that 
harbours many immediate and long-term risks. Although overall mortality from the surgery is 
only 1-2%, almost all patients experience often severe side effects, including diarrhoea, weight 
loss, fatigue, iron and Vitamin B12 deficiencies, and difficulty eating (Norton et al., 2007). 
Therefore, there is an urgent need for a highly effective, relatively non-invasive treatment for 
HDGC. 
 




Ideally, a chemoprevention strategy will be developed for HDGC, where patients can take a 
regular dose of highly specific chemotherapy to prevent the onset of the HDGC phenotype. 
This therapy would utilise a compound that selectively kills cancerous cells while leaving 
normal cells largely unharmed. However, the development of such a drug is no small 
undertaking. For starters, cancerous cells, though standout in phenotype, are often only subtly 
different genetically from their non-cancerous equivalents. In addition to this, further 
difficulties arise when the gene in question is a tumour suppressor with a loss of function 
mutation, rather than an oncogene with a gain of function mutation. The fully or partially 
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silenced products of mutated tumour suppressors are pharmacologically elusive. Drugs are 
typically designed to inhibit proteins, so the pharmacologic restoration of a silenced function 
is fundamentally difficult (Iglehart & Silver, 2009). The circumvention of this problem lies 
within the strategic targeting of cellular vulnerabilities – an approach known as synthetic 
lethality.  
 
Originally defined in 1946 by geneticists working on the fruit fly, synthetic lethality describes 
the relationship between two genes, where the loss of one gene does not impact cell viability, 
however the additional loss of the second gene will induce cell death (Dobzhansky, 1946).  
This concept has since been thoroughly explored, revealing itself as a promising new area for 
cancer therapy development (Chan et al., 2011; Ferrari, Lucca, & Foiani, 2010; Kaelin, 2009).  
 
Processes crucial to cell survival are often achieved through multiple redundant cell signalling 
pathways (Lord, Tutt, & Ashworth, 2015). This means that the inactivation of one pathway 
does not necessarily result in cell death. Rather, the process is carried out by another 
compensatory pathway – a concept known as functional buffering.  This redundancy is at the 
crux of why cancerous cells can survive despite major disruptions in integral signalling 
pathways. In cancer cells where a major pathway has been silenced, these compensatory 
pathways can be exploited as cellular vulnerabilities. In other words, synthetic lethal genes can 
be utilised as novel therapeutic targets for cancers caused by the loss of a tumour suppressor 
gene by inducing cell death in cancerous cells, while leaving non-cancerous cells largely 
unharmed.  
 
The first synthetic lethal relationship to be utilised as an anticancer therapy was established in 
2005 between the genes BRCA1/2 and polyADP ribose polymerase (PARP) (Bryant et al., 
2005; Farmer et al., 2005). This led to the development of PARP inhibitors as a 
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chemotherapeutic drug for breast cancer, which exploit the vulnerabilities surrounding DNA 
repair in BRCA1/2 negative breast cancer cells. More recently, several other synthetic lethal 
relationships have been discovered and explored as potential therapeutic targets, such as the 
tumour suppressor P53 with ATR, a key determinant of replication fork stability (Reaper et al., 
2011; Ruzankina et al., 2009; Sangster-Guity, Conrad, Papadopoulos, & Bunz, 2011). In the 
case of HDGC, potential synthetic lethal drug targets are genes implicated in pathways that 
compensate for the homozygous loss of CDH1. A particular focus will be put on genes where 
pharmacologic inhibition will be easily attainable, such as those coding for kinases and other 
enzymes (Kaelin, 2005).  
 
Synthetic lethality provides a novel approach to the field of cancer therapy, which in some 
areas has fallen into a state of stagnancy. It is a solution to the frustrations of crippled or 
silenced tumour suppressor genes, previously deemed undruggable. It competes with the idea 
that a new mutation is a cancer cell’s strength, a new barrier to treatment, instead allowing 
them to be seen as potential lethal vulnerabilities to be exploited. Treatment development using 
this approach can be rapid, either through using new compounds uncovered with chemical 
screens, or by utilising existing compounds and licenced drugs for even faster implementation 
(Lord et al., 2015). 
 
1.3.2 Possible Synthetic Lethal Candidates 
 
The identification of novel synthetic lethal targets can be done through an extensive screening 
process. The goal of a synthetic lethal screen is to reveal genes which when chemically 
inhibited or transcriptionally silenced, inhibit cells harbouring the genetic mutation of interest 
– usually a tumour suppressor gene.  
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The inherent complexity of cell signalling networks make synthetic lethal interactions difficult 
to predict. However, high throughput RNAi screening has been used as an unbiased approach 
to identify genes in a synthetic lethal relationship with CDH1 (Telford et al., 2015). Previous 
work at the Cancer Genetics Laboratory has been done to identify potential synthetic lethal 
candidates for CDH1, as well as compounds capable of inducing the synthetic lethal effect.  
 
Both an siRNA screen targeting 18,120 genes and a known drug screen of 4,057 drugs have 
been completed. These screens identified many lead synthetic lethal candidates, including G-
protein coupled receptor (GPCR) signalling proteins and cytoskeletal proteins (Telford et al., 
2015). Subsequent drug screening and bioinformatic work has built on this, helping to identify 
the PI3K/AKT cell survival signalling pathway as a key pathway in maintaining CDH1 negative 
cell viability, and therefore a potential target for synthetic lethal drugging (Bougen-Zhukov et 
al., 2019, manuscript in preparation).  This pathway is described in more detail in section 1.6. 
 
1.4 Current models for HDGC 
 
Cancer is an exceptionally complex disease, which requires appropriately sophisticated models 
to facilitate its research. Unfortunately, models of human cancers often struggle to recapitulate 
the incredibly diverse and ever-changing nature of in vivo cancerous tissue, while maintaining 
a suitable level of throughput. As a result of this, for a long time the price paid for complexity 
was reduced throughput. Researchers had to jump between simple, high throughput disease 
models such as transformed 2D cell lines, and complex, low throughput animal models in order 





1.4.1 2D cell lines 
 
Transformed 2D cell lines are a well-established and thoroughly validated model for cancer. 
They provide a platform for the study of cancer in human cells and are easily manipulated, 
robust, tractable and rapidly expandable (Neal & Kuo, 2016). Their ability to be genetically 
and pharmacologically manipulated with relative ease means that cell lines can model specific 
mutations and cancer subtypes, while providing an ideal platform for preliminary, high-
throughput drug screening.  
   
However, without undermining their significant benefits, it must be acknowledged that as 
models of cancer, 2D cell lines are acutely flawed. Their inherent simplicity means that they 
fall short of accurately depicting the true nature of cancerous tissue, which harbours high levels 
of heterogeneity and heavily involves the tumour microenvironment. Although easily 
expandable, their long-term passage inevitably causes cells to evolve and pick up mutations, 
which if not regulated means that eventually they will no longer be an accurate representation 
of the tissues from which they were derived and intend to reflect (Neal & Kuo, 2016). 
Furthermore, cancer-specific cell lines often have uncharacterised background mutations, 
which can have an effect on their drug response and impact other experimental elements in an 
unprecedented manner. These limitations are at the root of why numerous anti-cancer 
treatments developed from 2D cell line screening have failed in clinical trials (Caponigro & 
Sellers, 2011; Kamb, 2005). 
 
Cell heterogeneity and extracellular matrix interactions are at the core of cancer initiation and 
progression (Egeblad et al., 2010). Tumours, often incorrectly thought of as a group of cancer 
cell clones, are in actuality an organ – albeit a structurally and functionally abnormal one – 
comprised of differentiated cells, stem cells, and an extracellular matrix. Understanding the 
complex and dynamic interactions between heterogenic cancer cells within a tumour, as well 
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as with their microenvironment and the body as a whole, is crucial to the development of 
effective cancer treatments and prevention (Egeblad et al., 2010). Ultimately, this level of 
heterogenic complexity cannot be obtained with 2D models. As such, despite the benefits of 
2D cell modelling, the technique is inherently limited and thus can only be effectively used as 
a first step in disease modelling and treatment research. 
 
As a first in vitro screening step in our laboratory, two isogenic CDH1-/- cell lines have been 
characterised (Chen et al., 2019, manuscript in preparation). The first, MCF10A, is a human 
epithelial breast cell line. This is a non-cancerous cell line with a ‘clean’ genetic background, 
suitable for this project due to HDGC’s link to LBC. The second cell line used, NCI-N87, is a 
gastric cancer cell line with a high rate of background mutations. Although more challenging 
to work with due to its unpredictable and changeable behaviours, this cell line reflects the more 
complex genomic landscape of cancerous tissue. 
 
1.4.2 Animal models 
 
Animal models, including patient-derived xenografts and genetically-engineered mouse 
models, are highly complex, inhabiting the opposing end of the cancer model spectrum to 2D 
cell lines. They are inclusive of a tumour microenvironment and heterogenous cell populations, 
meaning they are a more accurate model of the cancer they are depicting in comparison to 2D 
cell lines – both for the study of disease and drug screening (Neal & Kuo, 2016). However, as 
a result of their increased complexity, they lack the easy manipulation and expandability of 
cell lines. In addition to this, they are time, money and resource intensive. Therefore, they 
cannot provide the high-throughput modelling often required in cancer research. It has been 
observed that the tumour microenvironment can confer drug resistance through regulating the 
distribution of the drug or by releasing signals that prevent cell death (Egeblad et al., 2010). 
Therefore, having a model that is inclusive of this microenvironment, such as an animal model, 
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is imperative to studying disease and developing therapies. However, to maximise efficiency 
in the process, they should only be used late in the piece as a near-final step, preceded by 
higher-throughput, more amenable models.  
 
Modelling a disease as multi-faceted as cancer is an endlessly challenging task for scientists in 
the field. As discussed, there are two opposing yet complementary movements in cancer 
modelling at present: firstly, a push towards more complex, more representative in vitro 
models, and secondly, a drive in the other direction that moves away from using high volumes 
of animal models and instead explores more ethical, high-throughput options. These two 
movements, opposite in direction but aligned in intention, meet in the middle and ‘find 
themselves’ at organoids. This medium-throughput cellular model of substantial complexity 
fills a previously vacant research niche, providing us with a platform for novel discovery in a 






Organoids are 3D structures comprised of both differentiated and stem cells, which in part 
recapitulate the organisation and function of target organs. Propagated in vitro, these spherical 
cell cultures have the delicate organisation of the in vivo gastric gland, albeit on a smaller, 
simpler scale. They can be generated from various different cell types, including induced 
pluripotent stem cells (iPSCs), embryonic stem cells and adult stem cells (Fatehullah, Tan, & 
Barker, 2016; Yin et al., 2016) – both mouse (Li et al., 2014; Seidlitz et al., 2018) and human 
(McCracken et al., 2014; Pompaiah & Bartfeld, 2017; Seidlitz et al., 2018). Organoids provide 
an easily manipulated disease model with high-throughput potential, while maintaining a 
relatively complex level of structure and organisation. Though they do not replace either 2D 
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cell lines or animal models, organoids fill their own valuable niche in disease modelling. They 
harbour the ability to facilitate medium throughput, specific screening of drugs, provide a more 
comprehensive look at disease progression and mechanisms, and can aid in the development 
of personalised medicine (Xu et al., 2018).  
 
Despite their undeniable benefits, like all models, organoids do not come without limitations. 
There are things that they cannot tell us, and thus we should not ask of them. Their main 
purpose is to act as a medium-throughput, medium-complexity screening tool for novel 
treatments, and to allow for a closer look at disease mechanisms. Organoids cannot provide 
comprehensive information on the extensive effects of cancer outside of the cancer cells, nor 
can they tell us about any long-term or downstream drug effects. Furthermore, despite their 
complex structure, they still do not harbour the complete cancer microenvironment that is so 
crucial to the thorough study of the disease. As a result, they should be considered 
complementary to, rather than replacive of, current in vitro and in vivo cancer models.  
 
In recent years, organoids have increased substantially in popularity as a research tool. At 
present, they have been developed for virtually every human organ, including brain (Eiraku et 
al., 2008; Lancaster et al., 2013), intestine (Ootani et al., 2009), breast (Simian et al., 2001), 
lungs (Rock et al., 2009) and stomach (Mahe et al., 2013; McCracken et al., 2014; Nadauld et 
al., 2014; Pompaiah & Bartfeld, 2017; Seidlitz et al., 2018).  
 
1.5.2 Gastric organoids 
 
In recent years, gastric organoids, or gastroids, have been used to study cancer (Li et al., 2014; 
Seidlitz et al., 2018; Vlachogiannis et al., 2018), as well as other diseases such as H. pylori 
infection (McCracken et al., 2014; Pompaiah & Bartfeld, 2017; Schlaermann et al., 2016). The 
study of gastrointestinal cancers has advanced rapidly of late, owing in part to the organoid 
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model, which has made the investigation of oncogenic processes significantly more accessible 
(Neal & Kuo, 2016). Organoids can be used to investigate many of the well-established 
hallmarks of cancer using various assays, including cell proliferation, cell death, resistance to 
growth suppression, and invasion capabilities. Furthermore, organoids have proved to be a 
valuable drug screening tool, both for the discovery of novel treatment compounds, for 
example using an organoid biobank (Van De Wetering et al., 2015), and for the pre-screening 
of already established treatments on patient-derived organoids (Seidlitz et al., 2018; 
Vlachogiannis et al., 2018). They provide a sufficiently accurate measure of the efficacy of the 
drug and the in vivo response, often reflecting the results of clinical trials more accurately than 
equivalent 2D cell line screens (Jabs et al., 2017). Because of this, they are one of the primary 
drivers behind the emerging area of personalised medicine. 
 
1.5.3 Organoid culture methods 
 
There are currently two primary methods used for the culture of organoids: the submerged 
model and the air-liquid interface (ALI) model. The submerged model requires organoids to 
be grown embedded in Matrigel and completely submerged with growth media (Barker et al., 
2010). The ALI method is an adaption of this, where the organoids are embedded in collagen 
in a transwell insert, which sits in an outer well of growth media (Ootani et al., 2009). This 
allows the organoids to have an air supply for oxygenation, as well as a supply of liquid growth 
media, which diffuses through the semi-permeable bottom of the transwell insert. The collagen 
mimics the structure of collagen found in vivo, and acts as an extracellular matrix for the 
organoids. The air-liquid interface (ALI) method encourages the culture of epithelial-
mesenchymal hybrid structures from primary tissue (Neal & Kuo, 2016), and therefore is a 
suitable method for generating gastroids for studying epithelial cancers such as HDGC. In 
comparison to the submerged model, the ALI method has been described as the system 
providing the most accurate recapitulation of the in vivo situation (Katano et al., 2013a). It 
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establishes a polar environment, with air exposure on one side and a source of growth factor-
containing liquid on the other. This is intended to mimic the in vivo environment for epithelial 
tissue, where a lumen lies on one side and a mesenchymal layer on the other side, encouraging 
a polar cell phenotype. 
 
In the ALI model, organoids are co-cultured with myofibroblast cells, also embedded in the 
collagen, which provide a stromal-like environment and aid in maintaining the stem cell niche 
(Katano et al., 2015). The endogenous factors released by the myofibroblasts facilitate the 
growth of the organoids without the need for exogenous growth factors added into the media. 
A successful ALI culture will produce 3D, spherical structures with active proliferation in both 
the stem and epithelial cell populations. In addition to this, there is often an accumulation of 
apoptotic cells in the lumen, due to the rapid turnover rate of cells within the organoids (Katano 
et al., 2013b).  
 
1.5.4 Conditional knockout mice 
 
Loss-of-function studies can be easily performed using organoids derived from the stem cells 
of a genetically modified mouse with a mutant target gene. Moreover, inducible systems for 
conditional knockout cells can be added through the insertion of a Cre-inducible construct into 
the genome. This allows for the temporal and special control of the expression of a target gene.  
 
The Cre-loxP construct is a bacteriophage P1 recombination system that can be utilised to 
mutate a gene of interest in an inducible manner (Schwenk, Baron, & Rajewsky, 1995). The 
system uses the Cre recombinase enzyme to catalyse target-specific DNA recombination 
between two loxP sites. If the loxP sites are placed flanking an essential part of a target gene, 
expression of Cre will result in the deletion of that essential segment of target DNA, and 
consequently silence the gene of interest.  
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This system is especially useful for genes, such as CDH1, that are embryonic lethal when 
homozygously inactivated, as it allows for temporal and spacial control of the knockout (Deng, 
2012). In the case of HDGC, patients are born with only a heterozygous loss of the gene and 
lose the second copy somatically later in life. Therefore, induction of the homozygous loss of 
Cdh1 in an established organoid is comparable to HDGC’s initiating step. The mutational 
silencing of Cdh1 in the mice can be restricted to specific cell types determined by the promotor 
Cre is placed under. For example, in order to knock out Cdh1 from epithelial cells, Cre is 
placed under the promotor of Cd44, a gene that is highly expressed in the stem cells of several 
epithelial tissues (Senbanjo & Chellaiah, 2017).  
 
1.6 PI3K/AKT pathway 
 
1.6.1 Overview and role in cancer 
 
The PI3K/AKT pathway is a crucial regulator of cell proliferation and survival and closely 
linked with E-cadherin. Co-immunoprecipitation has been used to show PI3K’s association 
with E-cadherin at the adherens junction and that AKT is activated by cell-cell adhesion (Pece, 
Chiariello, Murga, & Gutkind, 1999). E-cadherin-mediated activation of the PI3K/AKT 
pathway is crucial for the repression of programmed cell-cell death signals and the regulation 
of cell overgrowth through contact inhibition.  
 
Deregulatory changes in cell signalling pathways underlie the development of many cancers. 
The PI3K/AKT pathway plays an important role in the regulation of many essential cell 
functions, including proliferation, metabolism, growth, survival and protein translation (Tapia 
et al., 2014). Due to its integral role in cellular function, deregulation of this pathway is 
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frequently found to play a role in the development and progression of a diverse range of 
malignancies, including gastric cancer. 
 
Protein expression studies have shown that the majority of proteins implicated in the PI3K/AKT 
pathway are over-expressed or phosphorylated in gastric tumour tissue, when compared to 
normal gastric tissue of the same patients (Tapia et al., 2014). The main exception to this is the 
tumour suppressor gene PTEN, which is downregulated. This pathway can therefore be 
considered as a potentially effective target for gastric cancer therapy. Specifically, PI3K and 
AKT have been reported as being overexpressed in 80 and 82% of cases, respectively (Ye, 
Jiang, Xu, Zhou, & Li, 2012). This information, along with the screening previously done in 
our laboratory, has flagged the PI3K/AKT pathway as a strong contender for synthetic lethal 
targeting.  
 
In normally functioning pathways, growth factor signalling is mediated by PI3K through AKT, 
which activates mTORC1 when upstream signals are activated (Tapia et al., 2014). mTORC2 
acts through negative feedback to prevent AKT activity. When the pathway is deregulated in 
cancer cells, PI3K and AKT have increased levels of activity, which results in increased 
mTORC1 activity and decreased negative feedback of mTORC2. These changes result in an 
uncontrolled increase in cancer-enabling cellular functions including cell growth, proliferation, 
autophagy, angiogenesis and protein synthesis. Recognition of the importance of this pathway 
in cancer has led to the development of a new class of mTOR-targeting anticancer therapies 
that have been yielding promising results. Drugs that inhibit other components of the pathways, 
including AKT and PI3K, are also emerging as promising options for cancer therapies (Brown 






Figure 1.2 | Schematic diagram of the PI3K/AKT pathway. Growth factor signalling is 
mediated by PI3K through AKT, which activates mTOR when upstream signals are activated. 
This pathway regulates cell growth, proliferation and survival.  
 
It is important to note that the PI3K/AKT pathway regulates a wide range of cellular processes, 
exceeding those involved in tumorigenesis. Therefore, proteins selected as therapeutic targets 
must be carefully chosen as to inflict minimal disruption on other integral PI3K/AKT-
dependent process not involved in tumorigenesis. For example, due to its regulatory role on 
insulin metabolism, PI3K inhibitors have the potential to disrupt glucose homeostasis (Luo, 
Manning, & Cantley, 2003). A solution to this is to target proteins further downstream in the 






This project aims to use gastric organoids derived from engineered mice as a model for HDGC 
cancer progression. This will be done through an initial optimisation phase, where organoid 
culture techniques and qualitative analysis methods will be assessed. Qualitative measurements 
will include morphology, proliferation rate and cell composition of the organoids. These will 
be measured using techniques such as light, fluorescence and confocal microscopy, as well as 
immunofluorescence staining.  
 
The second part of this project will be a drug testing phase, where drugs that have previously 
been identified as potentially synthetic lethal will be applied to Cdh1-negative and Cdh1-
positive organoids and their effects measured.  
 
Ultimately, this thesis aims to prove the hypothesis that conditional Cdh1-knockout organoids 
can be used to identify synthetic lethal drugs with the potential to be used as treatments for the 






Chapter 2: Materials and Methods 
 
  
2.1 List of reagents  
 
 
0.05% trypsin solution – Prepared in lab (Appendix A) 
Antibody diluting buffer – Prepared in lab (Appendix A) 
Anti-Ki67 Antibody – Abcam, USA 
Anti-rat IgG (H+L), (Alexa Fluor 488) – Cell Signalling, USA 
ARQ-092 – Selleckchem, USA 
Blocking buffer – Prepared in lab (Appendix A) 
CD44 Monoclonal Antibody – Invitrogen, USA 
Chicken anti-Rabbit IgG Secondary Antibody (Alexa Fluor 594) – Invitrogen, USA 
Dimethyl sulfoxide (DMSO) – Sigma-Aldrich, USA 
Donkey anti-Goat IgG Secondary Antibody (Alexa Fluor 488) – Invitrogen, USA  
Dulbecco’s modified Eagle’s medium and F12 (DMEM-F12) – Thermo Fisher 
Scientific, USA  
Endoxifen Hydrochloride Hydrate – Sigma-Aldrich, USA 
Ham's F-12 Nutrient Mix, GlutaMAX™ Supplement – Thermo Fisher Scientific, USA 
Human/Mouse E-cadherin Antibody – R&D Systems, USA 
Foetal bovine serum (FBS) – Invitrogen, USA  
Foetal horse serum (FHS) – Invitrogen, USA 
Freezing medium – Prepared in lab (Appendix A)  
Gentamicin (Gibco) – Thermo Fisher Scientific, USA 
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Methyl-β-cyclodextrin – Sigma-Aldrich, USA 
MK2206 – Selleckchem, USA 
Nitta cellMatrix Collagen Gel Culturing Kit – Novachem, Australia 
Paraformaldehyde (PFA) – BDH Limited, England  
Phosphate buffered saline (PBS) solution – Prepared in lab (Appendix A)  
ProLong Gold antifade reagent with DAPI – Thermo Fisher Scientific, USA 
ProLong Gold antifade reagent without DAPI – Thermo Fisher Scientific, USA  
Triton X-100 – Sigma-Aldrich, USA 
Vorinostat (SAHA) – Selleckchem, USA 
 
2.2 List of equipment 
 
 
0.2 µm hydrophilic syringe filter – Sartorius, Spain  
1 mL cryovials – Nunc, Denmark  
10 cm Cellstar cell culture dish – Greiner, Germany 
1.5 mL Eppendorf tubes – Sigma-Aldrich, USA 
30 mm Cellstarcell culture dish – Greiner, Germany  
5 mL Eppendorf tubes – Sigma-Aldrich, USA 
60 mm Cellstar cell culture dish – Greiner Bio-One, Germany  
10 mL serological pipettes – Greiner Bio-One, Germany  
15 mm cell culture dish – Greiner Bio-One, Germany 
15 mL Falcon tubes – BD Biosciences, USA  
22x22 mm glass cover slips – Menzel-Glaser, Germany  
50 mL Falcon tubes – BD Biosciences, USA 500 mL filter system - Corning, USA  
75 mL cell culture flasks – Greiner Bio-One, Germany  
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75x25 mm Gold Seal microscope slides – Thermo Fisher Scientific, USA  
Centra 3C centrifuge – International Equipment Company, USA  
CO2 cell culture incubator – Binder, Germany  
Dual chamber cell counting slides – Bio-Rad, USA  
Eclipse Ti Inverted Microscope System – Nikon, USA  
Eppendorf Mini Spin Plus centrifuge – Sigma-Aldrich, USA 
Fuji LAS-3000 ECL Imaging System – Thermo Fisher Scientific, USA  
Millicell cell culture inserts (0.4µm, 30mm) – Merck Millipore, Ireland 
Mr. Frosty 5100 Cryo 1°C Freezing Container – Thermo Fisher Scientific, USA  
Olympus CK2 Microscope – Olympus, New Zealand  
Olympus Fluoview FV1000 Confocal Microscope – Olympus, New Zealand 
TC10 Automated Cell Counter – Bio-Rad, USA  
Tissue culture hood – EMAIL, Australia  
Water bath – Semco, USA 
 
2.3 Software  
 
 





All animal procedures were approved by the University of Otago Animal Welfare and 
Ethics Committee (DET35/15) and were performed in accordance with University 
guidelines and regulations.  
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2.5 Myofibroblast culture 
 
 
Myofibroblasts are adherent cells that are phenotypically similar to both fibroblast and smooth 
muscle cells. They are found in the subepithelial region of mucosal surfaces, including the 
gastrointestinal tract. Their role is both supportive and paracrine, aiding in the regulation of 
crypt structure and maintenance of the stem cell niche – hence their importance in gastric 
organoid culture (Hinz et al., 2007). 
 
Myofibroblasts used here were previously isolated in our laboratory from a wildtype C57 black 
6 mouse (C57BL/6) using a protocol adapted from Pastuła et al. (2016). This myofibroblast 
cell line (MFB11) was used for co-culture with organoids from passage 8, and no later than 
passage 17. MFB11 cells were cultured at 37 °C with 5% CO2 in 75 mL cell culture flasks 
(Greiner). MFB11 complete culture media was made using Gibco DMEM/F-12 GlutaMAX™ 
(80%) supplemented with filtered (0.22 µm filter) fetal bovine serum (FBS) (20%).  
 
2.5.1 Myofibroblast passage 
 
MFB11 cells at 80-90% confluence were passaged. Following media aspiration, cells were 
washed once with 5mL phosphate buffered saline (PBS) and then incubated in 4 mL of 0.05% 
trypsin at 37 °C for 8 minutes. 8 mL of complete culture media was added to the flask and 
suspended cells transferred to a 15 mL Falcon tube. Cells were centrifuged at 700 rpm (Centra) 
for 5 minutes to pellet. Supernatant was then removed and cells resuspended in 1 mL of 
complete culture media. Cells were then counted using the TC10 automated cell counter (Bio-
Rad) and re-seeded. Cells were re-seeded at 1.5x105 cells per 75 mL cell culture flask 
(approximately 1/10 of a confluent flask). Complete culture media was changed every 3 days 
and cells passaged every 7 days.  
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2.5.2 Myofibroblast freezing 
 
For cryopreservation, cells were suspended in 1 mL of freezing media comprised of 80% 
complete culture media, 10% FBS and 10% Dimethyl sulfoxide (DMSO) in cryovials (Nunc). 
Cells were frozen down at 2x105 cells per cryovial. Cells were frozen to -80 °C in a Mr FrostyÔ 
(Thermo Fisher Scientific) overnight and then transferred to liquid nitrogen (LN2) for long term 
storage.  
 
2.5.3 Myofibroblast resurrection 
 
Frozen myofibroblast cells were removed from LN2 and defrosted in a 37 °C water bath. After 
defrosting, cells were immediately transferred to 15mL Falcon tubes containing 5 mL of 
complete culture media and pelleted by centrifugation at 700 rpm (Centra) for 5 minutes to 
pellet. Supernatant was then removed and cells were resuspended in 1 mL of complete culture 
media. Cells were seeded in 75 mL cell culture flasks (one vial into one flask) with 10 mL 
complete culture media. Media was changed after 24 hours to remove any residual DMSO, and 
then every 3 days.  
 
2.6 Organoid culture 
 
 
2.6.1 Mouse euthanasia and stomach extraction 
 
Organoids were generated using stem cells from inducible knockout mice with a Cre-Lox 
system controlling both Cdh1 and the fluorescent marker protein TdTomato under the CD44 
promotor (CD44-cre/Cdh1-/-/TdTomato). Mouse pups were used on day 1-2 after birth. 
 
After delivery, mice were euthanised through decapitation using a sterile single-edge razor 
blade in a 10 cm culture dish. Mice were then transferred to a sterile tissue culture hood for 
stomach extraction. A sterile pair of dissection scissors and forceps were used to remove the 
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mouse stomach. Forceps were used to hold the mouse in place while the scissors were used to 
make a small horizontal incision just above the stomach. The location of the stomach was 
known, as the small white organ was visible through the semi-transparent skin on the abdomen 
of the mouse pup. The stomach was removed through the small incision using the forceps and 
detached from the rest of the gastrointestinal tract using the scissors. The stomach was then 
placed into the lid of the 10 cm dish, where any congealed milk was expelled by pressing down 
gently on the stomach tissue using forceps.  
 
Using a new pair of sterile forceps, the stomach was washed four times in four separate 30 mm 
cell culture dishes, each containing 100 µL of PBS with added Gentamicin (Life Technologies) 
at 50 µg/mL. The washed stomach was then placed into a 1.5 mL Eppendorf tube containing 
100 µL of PBS with Gentimicin (50 µg/mL). Using a new pair of sterile scissors, stomach was 
then minced in the Eppendorf tube (approximately 15 cuts). Using a second, smaller pair of 
scissors, the stomach was minced further until the tissue was in pieces < 0.5 mm3. Equipment 
was sterilized between each individual mouse.   
 
2.6.2 Organoid seeding 
 
Organoids were cultured using an air-liquid interface (ALI) method (Ootani et al., 2009) to 
promote the development of epithelial/mesenchymal structures. This culture system is 
comprised of a 30 mm Millicell transwell insert (Millipore) with a raised, permeable (0.4 µm) 
bottom that sits in a 60 mm cell culture dish (Greiner).   
 
Prior to seeding stomach tissue, collagen containing MFB11 cells was prepared. 2.4 mL (1.2 
mL per layer) of collagen mix was needed for each organoid dish (one stomach per dish). It 
was recommended that when preparing collagen, the total volume made should be 30% more 
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than what was required, due to the amount lost in the tube/pipette during preparation and tissue 
seeding. 
 
cellMatrix™ Collagen Gel Culturing Kit (Nitta) was prepared as shown in table 2.1: 
 
Component Concentration (%) 
cellMatrix™ collagen solution Type I-A  80 
10x Ham’s F-12 growth media 
(containing MFB11 cells) 
10 
Sodium bicarbonate buffer solution 10 
 
Table 2.1 |Concentration of components in cellMatrix™ collagen gel culturing kit for use 
in the ALI organoid model.   
 
To prepare the collagen mix, myofibroblast cells were first removed from their 75 mL cell 
culture flasks. Approximately 1x106 MFB11 cells were needed per organoid dish (5x105 per 
1.2 mL layer). To remove cells, media was aspirated, cells were washed once with 5mL 
phosphate buffered saline (PBS) and then incubated in 4 mL of 0.05% trypsin at 37 °C for 8 
minutes. 8 mL of complete culture media was added to the flask and suspended cells transferred 
to a 15 mL Falcon tube. Cells were centrifuged at 700 rpm (Centra) for 5 minutes to pellet. 
Supernatant was then removed and cells resuspended in 1 mL of 10x Ham’s F-12 growth media 
(Nitta collagen culturing kit). Cells were then counted using the TC10 automated cell counter 
(Bio-Rad). 
 
Collagen mix was prepared on ice in either a 5 mL Eppendorf tube or 15 mL Falcon tube 
(depending on volume required) using the ratio in the above table. CellMatrix™ collagen 
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solution Type I-A was added first, followed by 10x Ham’s F-12 growth media containing MFB11 
cells. Depending on concentration of myofibroblast cells in F-12 growth media, additional 
media without MFB11 cells was added in order to make up required volume. Finally, the 
sodium bicarbonate buffer solution was added, and tube contents was thoroughly mixed using 
a 1 mL pipette. 1.2 mL of collagen mix was added to the transwell insert (sitting within 60 mm 
cell culture dish). This was then left to set at 37 °C for approximately 30 minutes. Remaining 
collagen/MFB11 mix was kept on ice until needed to prevent it from setting. 
 
The tube containing the minced stomach tissue in PBS from section 2.6.1 was centrifuged at 
800 rpm (Eppendorf) for 3 minutes. Supernatant was then removed and stomach tissue re-
suspended in 1.2 mL of collagen mix. Collagen mix containing stomach tissue was then 
transferred to the transwell insert, pipetted gently in an even layer on top of the first layer of 
collagen (containing MFB11 cells but no stomach tissue). The second layer of collagen was 
then left to set at 37 °C for approximately 30 minutes. Once set, 3 mL of complete organoid 
media, comprised of F-12 GlutaMAX™ supplement (80%) and filtered (0.22 µm filter) FBS 
(20%), was added to the outer 60 mm dish. Dish was then placed in 37 °C incubator with 5% 
CO2  to culture.  
 
2.7 Organoid induction 
 
2.7.1 Knockout induction 
 
Knockout of Cdh1, and activation of TdTomato, is induced with the addition of endoxifen to 
the media (metabolite of tamoxifen). For dishes intending to harbour induced (KO) organoids, 
endoxifen is added to the complete organoid media (80% F-12 GlutaMAX™ supplement and 
20% FBS) at a concentration of 5 µM on day 0. For control plates, an equivalent amount of 
DMSO was added to the media at the same timepoint.  
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2.7.2 Knockout efficacy calculations 
 
To measure Cdh1 knockout efficacy in the organoids, area measurements were taken using 
confocal Z-stack images. Using the Measure tool on Fiji (ImageJ), the total area of Cdh1 
negative cells within an organoid on a single confocal Z-stack image was measured in pixels, 
and then calculated as a percentage of the entire organoid area (excluding the lumen) in that 
image. This was done for 10 different Z-stack images in each organoid. The average percent 
knockout (mean) of the 10 images was then calculated and that value used as the approximate 





2.8.1 Staining  
 
Transwell inserts were removed from 15 mm dishes, and remnant media rinsed from the bottom 
using a Pasteur pipette. One single use, sterile, stainless steel surgical blade (Swann-Morton) 
was then used to cut around the bottom of the insert and the collagen. Insert bottom was 
removed and the collagen placed on a 10 cm dish. Using two stainless steel surgical blades, 
segments of collagen containing the organoids being targeted for immunofluorescence were 
cut out. Cuts were made as close to the organoids as possible without inflicting any damage. 
 
Small collagen segments containing organoids were placed into 1.5 mL Eppendorf tubes (1-2 
segments per tube) containing 500 mL of 4% PFA and left to fix for 30-40 minutes. PFA was 
then removed from the Eppendorf, followed by 3x PBS washes in the tube. Organoids were 
then blocked and permeabilised using 500 mL of blocking buffer (BB) (10% FHS in PBS) and 
TritonX (0.5% final conc.) and left to incubate for 1 hour on a shaker in the dark at room 
temperature. After incubation, the blocking buffer was removed, followed by 1x PBS wash. 
500 mL Antibody diluting buffer (ADB) (10% foetal horse serum (FHS) and 2% FBS in PBS), 
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primary antibody and TritonX (0.1% final conc.) were then added to the Eppendorf and 
organoids were left to incubate overnight on a shaker in the dark at 4 °C.  
 
Primary antibody Dilution Secondary antibody Dilution 
E-Cadherin (goat) 1:100 Donkey anti-goat (488) 1:1000 
Ki67 (rabbit) 1:100 Chicken anti-rabbit (594) 1:1000 
CD44 (rat) 1:50 Goat anti-rat (488) 1:1000 
 
Table 2.2 | Primary and secondary antibody dilutions used in immunofluorescence on the 
organoids. 
  
ADB, primary antibody and TritonX were removed from the tube, followed by 3x PBS washes. 
500 mL ADB and secondary antibody (1:1000) were added to the tube, and organoids were 
left to incubate for 2 hours on a shaker in the dark at room temperature. Organoids were then 
washed 5x with PBS, and 3-4 drops of ProLong Gold antifade reagent with DAPI (Thermo 
Fisher) added to the tubes. Organoids were left to incubate in ProLong Gold with DAPI for 
approximately 15 minutes while bridge mounts were set up.  
 
2.8.2 Bridge mounting 
 
Collagen segments containing organoids were mounted on 25x75 mm microscope slides using 
a bridge mounting method. Bridge mounting utilises two pillar coverslips to reduce the extent 
to which organoids are flattened under the top coverslip. The small elevation of the top 
coverslip accommodates the height of the collagen (approximately 1 mm). For the supportive 
pillars, two 22x22 mm coverslips were placed at either end of the slide, held down using one 
drop of ProLong Gold antifade reagent without DAPI (Thermo Fisher). A segment of collagen 
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containing organoids was then transferred from the Eppendorf tube to the centre of the slide 
using a wide-bore pipette, and two drops of ProLong Gold antifade reagent with DAPI (Thermo 
Fisher) were placed on top. A final 22x22 mm coverslip was then placed on top of the organoid 
sample, slightly raised by the two underlying coverslips to allow for the height of the collagen 
segment. After 30 minutes, the perimeter of the slide was sealed with transparent nail varnish 
and left to dry for approximately 1 hour before microscopy.  
 
 
Figure 2.1 | Diagram of bridge mounting set up for organoid microscopy.  
 
2.8.3 Brightfield and Fluorescence microscopy  
 
All brightfield and fluorescence microscopy was done on an Eclipse Ti Inverted Microscope 
System (Nikon) using the Fuji LAS-3000 ECL Imaging System (Thermo Fisher Scientific). 
During organoid culture, daily brightfield images were taken to track growth. Images were 
taken of organoids in the transwell insert without removing them from the 60 mm dish. 
Additional fluorescence imaging using the TRIT-C filter was also carried out to track 
TdTomato fluorescence in the CD44-cre/Cdh1-/-/TdTomato mice during growth.  
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Following immunofluorescence, images were taken of fixed and stained organoids on each 
microscope slide. For imaging of E-cadherin and CD44 (both 488), the FIT-C filter was used. 
For imaging of Ki67 (594) and endogenous TdTomato (581), the TRIT-C filter was used. DAPI 
nuclei staining was imaged using the UV filter.  
 
2.8.4 Confocal microscopy 
 
Confocal microscopy was carried out using the Olympus Fluoview Confocal Microscope. For 
each organoid, between 20-30 Z-stack images were taken, depending on the size of the 
organoid.  
 
2.9 Drug screening 
 
 
2.9.1 DMSO toxicity testing  
 
To test DMSO tolerance, four dishes of organoids were first cultured using the method 
described in section 2.6. On day 2 of culture, DMSO was added to the complete culture media 
at a different concentration in each dish (0.2%, 0.1% and 0.05%). One dish was left untreated. 
Organoids were then placed in a 37 °C incubator with 5% CO2 to culture. Brightfield images 
were taken every 24 hours using the inverted microscope.  
 
2.9.2 Drug treatment 
 
For drug screening experiments, organoids were established as described in section 2.6. From 
initial seeding on day 0, organoids were cultured using complete culture media. For plates 
needing Cre induction, endoxifen was added to the media at a final concentration of 5 µM from 








Figure 2.2 | Diagram of the four plate conditions for each drug screening experiment.  
 
Organoids were left to culture in a 37 °C incubator with 5% CO2 for 48 h. After 48 h, media 
was removed and substituted for media containing the drug or solvent at the required 
concentration, determined using the IC50 values from initial 2D screening in our laboratory. 
Endoxifen was not replenished for plates containing KO organoids.  
 
Plates were imaged using the inverted microscope every 24 hours to track growth. After the 
organoids had been exposed to the drug for 96 hours (day 6 of growth) they were fixed analysed 






2.9.3 Quantification of organoid viability 
 
Brightfield images taken using the inverted microscope were analysed to quantify the effect of 
the drug. Using the measure tool on Fiji (ImageJ), the area of each organoid was outlined and 
measured on both the day 2 (0 h after drugging) and day 6 (96 h after drugging) images. These 
two measurements were then used to calculate the total percentage increase in growth for each 
organoid. Both the raw data and the averages could then be plotted on line and bar graphs, 
respectively. 
 
2.9.4 Statistical analysis 
 
Statistical analysis on organoid size was performed using a Wilcoxon rank-sum test, a 
nonparametric alternative to the two sample t-test. This is also known as the Mann-Whitney U 
test and is used for independent samples, differing from the Wilcoxon signed-rank test, which 






Chapter 3: Optimisation Results 
 
 
The conditional Cdh1 knockout organoids developed here are the first of their kind as a model 
for HDGC. The goal for this phase of the project was to optimise an array of different staining 
and imaging techniques to use in the characterisation of these novel organoids.  
 
Prior to beginning lab work, it was clear there were several challenges. Organoids of this 
nature, with a conditional Cdh1 knockout, are entirely novel to the field, and therefore require 
considerable characterisation. Although there are similar Cre-inducible mouse models with 
which to compare the knockout efficiency, which is highly variable (Leonhard, Roelfsema, 
Lantinga-Van Leeuwen, Breuning, & Peters, 2008; Mirantes et al., 2013), there are none that 
used this exact system and CD44 promotor to drive Cdh1 knockout in organoids. Further, we 
did not know how the knockout would impact the growth or stability of the organoids.  
 
3.1 Organoid establishment and growth  
 
To begin with, it was necessary to gain an understanding of the basic growth pattern of the 
organoids under our normal conditions. To do this, organoids were cultured from conditional 
knockout mice using the method described in section 2.6 and imaged in brightfield. After five 
biological replicates, a common growth pattern between the organoids was identified.  
 
Approximately 20 organoids could be developed and sustained from a single stomach in one 
dish, virtually all of which followed the same growth pattern (Fig. 3.1): 24h after primary tissue 
was seeded in the collagen, small, transparent cystic-like structures began to appear where 
organoids will eventually develop – usually in the centre of a segment of tissue. For a segment 
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of primary tissue to generate an organoid, it must contain a substantial population of gastric 
stem cells. Furthermore, there needs to be a small population of mesenchymal cells projecting 
outwards from the surface of the organoid to aid in growth factor production and delivery for 
the stem and progenitor cells (Katano et al., 2013b; Ootani et al., 2009). These myofibroblast 
populations and their potential origins are discussed further in Chapter 6. The transparent cysts 
present on day 1 begin to rapidly expand, forming spherical organoid structures within 48 
hours. The organoids continued to increase in size by approximately 0.1-0.4 mm each day, 




Figure 3.1 | Typical growth pattern of organoids from day 0-5. A) A representative 
organoid displaying the common growth pattern seen throughout the project. From primary 
tissue on Day 0, the beginnings of cystic structures form within 24 hours, which then go 
through a phase of rapid growth. Organoids expand into large, 3D spherical structures, reaching 
approximately 1.5mm in size by day 5. After day 5, growth continues at a decreased rate. B) 
















The cystic structure of the organoids is a mimic of in vivo gastric glands, which contain a 
monolayer of epithelial cells facing into a lumen. To keep experiments consistent, it was 
necessary to be able to clearly distinguish organoids from other tissue. It was determined that 
any structure that retained a prominent core of dark, opaque primary tissue should not be 
considered as an organoid. This included segments of primary tissue with a surrounding layer 
of rounded, transparent tissue or budding growths of stem cells (Fig. 3.2), as without a lumen 







Figure 3.2 | Primary tissue that has failed to generate organoids. Two segments of primary 
tissue (1 and 2) imaged in brightfield on day 0 and day 5. Tissue has generated a surrounding 
layer of rounded semi-transparent tissue (1) and small budding stem cell growths (2). However, 












Organoid 1 Organoid 2 
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3.2 Optimisation of imaging techniques  
 
After establishing an idea of what normal growth looked like in the organoids, suitable imaging 
techniques needed to be identified for use in subsequent experiments. Fluorescence imaging 
on an inverted microscope is adequate for gaining general insights, however it does not display 
anything beyond the outer surface of the organoid. Gaining a detailed understanding of the 
complete morphology of the organoids was an integral part of characterisation, so fluorescence 
imaging using a confocal microscope was explored as a method for the visualisation of both 
the surface and the centre of the organoid. 
 
The organoids in Figure 3.3 were all cultured for 3 days and stained with an E-cadherin 
antibody (488 - green) and DAPI (blue) using the immunofluorescence protocol in section 2.8. 
Two dishes were stained, one induced (KO) and one uninduced (WT), both containing 
approximately 10 organoids. Induced (KO) organoids are described fully in section 3.3. 
 
Figure 3.3A shows two organoids, one uninduced (WT) and one induced (KO), both imaged 
on the inverted fluorescence microscope. The images clearly show successful knockout in the 
induced (KO) organoid (right) and the complete staining of E-cadherin in the uninduced (WT) 
organoid (left). However, the inner lumens of the organoids are not visible. Figure 3.3B shows 
one uninduced (WT) organoid imaged using a confocal microscope. In contrast to Figure 3.3A, 











Figure 3.3 | Visualisation of the organoids through fluorescence imaging. A) Fluorescence 
imaging on an inverted microscope showing two organoids displaying immunofluorescence 
associated with the nuclei (DAPI – blue) and E-cadherin (488-green). Images show the general 
shape of both organoids, as well as the approximate knockout efficiency of E-cadherin in the 
induced organoid (pictured right). B) Fluorescence imaging on a confocal microscope showing 
one organoid displaying immunofluorescence associated with the nuclei (DAPI – blue) and E-
cadherin (488-green). Both a slice through the hollow centre (left) and the outer surface (right) 
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Figure 3.4 | A comparison of fluorescence imaging using an inverted and confocal 
microscope. One organoid showing immunofluorescence associated with E-cadherin (488-
green) and DAPI (blue) imaged on both an inverted microscope (left) and confocal microscope 
(right).  There is a distinct increase in resolution of the small organoid with the use of confocal 
microscopy. Single cells are more defined and overall organoid morphology and cell 
composition can be seen with increased clarity. 
 
 
3.3 Cdh1 knockout induction 
 
The organoids used throughout this project were generated from 1-2 day old mice harbouring 
conditional Cdh1 mutations (CD44-cre/Cdh1-/-). These mice were designed so that induction 
with endoxifen (a metabolite of tamoxifen) would lead to the expression of the Cre 
recombinase in CD44-expressing cells, leading to a homozygous frameshift deletion in Cdh1.   
This system circumvents the issue of the embryonic lethal phenotype caused by a homozygous 
Cdh1 knockout. Here, I have tested the functionality of this construct. 
 
For the initial knockout experiment, two dishes were set up, each with the tissue of one mouse 
stomach seeded in the collagen. Endoxifen was added to the media of one dish from 0 hours 
post-seeding at a concentration of 5 µM. Organoids were then left to grow for 5 days before 
being fixed and stained with an E-cadherin antibody (488-green) and DAPI (blue) using the 





immunofluorescence protocol described in section 2.8. The organoids were then imaged using 
the confocal microscope to analyse the knockout of E-cadherin.  
 
Confocal imaging of approximately eight organoids, four of which are pictured in Figure 3.5, 
showed successful knockout of E-cadherin, the degree of which varied markedly between 
individual organoids. Moreover, knockout occurred in seemingly random clusters, and no 
organoids appeared to have complete knockout. Uninduced organoids had a wildtype 
phenotype and displayed E-cadherin staining throughout the entire structure (Fig. 3.6). E-
cadherin staining had a regular, lattice-like appearance, consistent with the localisation of E-
cadherin to the adherens junctions at the cell membrane. There was variation in the general 
shape of the organoids – not all are exactly spherical – however this variation occurs in both 






Figure 3.5 | Induced (KO) organoids display successful induction of Cdh1 knockout. All 
four organoids have been stained with an E-cadherin (488-green) antibody and DAPI (blue). 
Confocal microscopy images show that knockout occurs in clusters throughout the organoid 
and varies in efficacy between organoids. In all organoids there is a portion of cells that retain 
functional E-cadherin (green-488) localised to the adherens junctions. The variation in tones 
of green is caused by the overlay of green and blue staining from cells in different planes in 















Figure 3.6 | Uninduced (WT) organoids show consistent E-cadherin expression. Confocal 
microscopy images of four typical organoids that have not been exposed to endoxifen in the 
media. E-cadherin staining is lattice-like and localised to the adherens junctions throughout the 
entire body of the organoids.  
 
After inducing Cre expression in three biological replicate plates of organoids, the approximate 
percentage of E-cadherin-negative cells in a random sample of organoids was determined by 
calculating the relative area of CDH1 negative cells as a percentage of the total area. This was 
completed for 10 slices through each organoid at different depths, and then the mean percentage 








This provided a reasonable estimate of the percentage of knocked out cells, and to what extent 





Table 3.1 | Approximate percentage of knocked out cells in a sample of organoids. After 
immunofluorescence and confocal imaging, the approximate knockout efficiency percentage 
was determined by calculating the total area of E-cadherin deficient cells (no green E-cadherin 
staining) as a percentage of the total area of the organoid. Organoid 20 displays slightly 





Together, these results show that E-cadherin can be successfully inactivated in organoids 
derived from neonatal mice using an inducible Cre system under the CD44 promotor. This 
happens in varying proportions of cells between different organoids. For the first time, this 
provides a novel model for the early stages of HDGC. 
 
3.4 Establishment of TdTomato organoids 
 
At this point in the project, mice harbouring a conditional Cdh1 knockout with an endogenous 
TdTomato fluorescent protein became available (CD44-cre/Cdh1-/-/TdTomato). TdTomato is 
a highly photostable tandem dimer that omits strong red fluorescence (emission wavelength 
581) (Shaner, Steinbach, & Tsien, 2005). The TdTomato gene contains a short insertion that 
abrogates the fluorescence of the protein. The insertion is flanked by LoxP sites which, when 
deleted by cre recombinase, leads to fluorescence.  Since Cre is expressed under the CD44 
promotor, Cdh1 negative cells should co-localise with red fluorescence. The addition of an 
endogenous fluorescent protein allows for the knockout to be visualised in real-time under the 
fluorescence microscope, without having to fix the organoids and run immunofluorescence. 
The addition of TdTomato should not alter the growth or morphology of the organoids in any 
other way aside from the added fluorescence, however, it was unknown whether the behaviour 
of the organoids would remain unchanged, or if the TdTomato protein would have unforeseen 
effects on the growth or structure of the organoids.  
 
To test the functionality of TdTomato, two dishes were set up, each with the tissue of one 
stomach from a 2 day old mouse seeded in the collagen. Endoxifen was added to the media of 
one dish from 0 hours post-seeding at a concentration of 5 µM. organoids were then left to 
grow for 5 days. 
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On first observation, the TdTomato fluorescence was visible within 24 hours of induction and 
increased in intensity over time. Importantly, organoids generated from TdTomato mice did 
not appear to have a different growth pattern to non-TdTomato organoids (Fig. 3.7). This 
remained true through all three initial biological replicates of this TdTomato growth 




Figure 3.7 | Growth pattern of TdTomato-expressing organoids. Fluorescence imaging 
showing the growth and TdTomato expression of a cluster of four organoids from day 1-4. 
Brightfield imaging shows the organoids expanding in size, while fluorescence imaging using 




Following successful induction of the Cdh1 knockout and TdTomato fluorescence, 
immunofluorescence experiments were carried out in order to validate the TdTomato 
fluorescence and ensure that cells positive for TdTomato were negative for E-cadherin staining. 
Immunofluorescence was carried out using an E-cadherin antibody (488-green) and DAPI and 
the protocol described in section 2.8. Organoids were then imaged using the confocal 
microscope to analyse TdTomato expression. 
 
Confocal imaging of approximately 10 induced (KO) and 5 uninduced (WT) control organoids 
revealed that in general, there was virtually no co-staining of E-cadherin in TdTomato 
expressing cells and E-cadherin expressing cells. When looking at the collated image of all the 
Z-stack images, distinct patches of TdTomato positive, E-cadherin negative cells are visible, 
although the majority of cells on the outer surface of the organoid are E-cadherin positive (Fig. 
3.8A). However, Z-stack images that expose the centre of the organoid show high numbers of 






Figure 3.8 | Immunofluorescence of TdTomato-expressing organoids. Confocal images of 
an organoid, both collated (A) and single slices (B) after immunofluorescence with E-cadherin 
(488-green) and DAPI. Endogenous TdTomato fluorescence is also visible (red). The collated 
image shows patches of TdTomato expression on the organoid surface. The single slices (in 
order of increasing depth going downwards) show TdTomato-expressing E-cadherin negative 
cells are present deeper in the organoid. 
 
 
Further investigation was done into the presence of TdTomato-expressing cells in the organoid 
lumen in order to gain a deeper understanding of what could be occurring. Confocal images of 
both uninduced (WT) and induced (KO) organoids were analysed, from both this and previous 




A closer examination of the lumen using a 3D reconstruction of the same organoid pictured in 
Figure 3.8 shows that the centre of the organoid is largely composed of E-cadherin negative 
cells (Fig. 3.9A). The cells appear adhered to the inner surface of the lumen, rather than 
detached. This phenomenon occurs in the majority of induced organoids, a selection of which 
are pictured in Figure 3.9B. This includes induced organoids without the TdTomato 
endogenous fluorescence. The vast majority of uninduced organoids have clear lumens with 
no cellular infiltration (Fig. 3.9C). This rich TdTomato core gives insight into how the 
organoids can have an outer surface which is primarily E-cadherin positive, but still have a 
high proportion of knocked out cells. 
 











Figure 3.9 | E-cadherin deficient cells cluster in the inner lumen of the organoid. A) 3D 
confocal image of an induced (KO) organoid that is expressing TdTomato (red) and has been 
stained with an E-cadherin (488-green) antibody and DAPI. The end of the organoid has been 
digitally removed to show the lumen enriched with TdTomato-expressing cells (schematic of 
shape shown alongside image). The exposed lumen shown alongside the outer organoid surface 
emphasises the difference in amount of E-cadherin positive cells between the two areas of the 
organoid. B) Confocal image slices through the centre of several induced organoids. E-cadherin 
deficient cells clustering in the lumen occurs regularly in knockout organoids, including non-
TdTomato organoids (far right). C) Non-induced organoids with a wildtype phenotype. These 










Through these experiments validating TdTomato, it was also observed that the endogenous 
fluorescence is continually expressed, significantly increasing in intensity over the first eight 
to ten days of culture. This is exemplified in Figure 3.10, which shows the progression of an 
organoid during the first 6 days of culture. When images are taken at the same exposure each 
day, the TdTomato fluorescence increases significantly in strength. This increase continues 





Figure 3.10 | TdTomato fluorescence increases over time. Fluorescence images of 
TdTomato expression (red) in the first 6 days of culture. The level of TdTomato fluorescence 
continues to increase over time. 
 
Together, these results show that TdTomato organoids can have their E-cadherin inactivated 
in the same way as non-TdTomato organoids. Further, that there is virtually no cross over 
between E-cadherin positive cells and TdTomato-expressing cells, which accumulate in the 




3.5 Immunofluorescence optimisation: collagenase 
 
As part of the optimisation of the immunofluorescence protocol, an experiment was done in an 
attempt to increase the level of clarity seen in fluorescence and confocal imaging and reduce 
the amount of background fluorescence. Despite incorporating several wash steps, when 
staining organoids in collagen there is a certain amount of unavoidable background 
fluorescence present (Fig. 3.11A). Removing the collagen prior to staining is one way of 
potentially removing this background fluorescence.  
 
To investigate this, collagen containing the organoid cultures was incubated in collagenase at 
a concentration of 1 mg/ml for 60 minutes at 37 °C prior to immunofluorescence staining on 
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day 5 of culture. Two dishes were used for this experiment, one induced and one uninduced, 
both containing approximately 10 organoids. After staining, organoids were imaged using 
fluorescence and confocal microscopy.   
 
The collagenase was effective in removing any background immunofluorescence (Fig. 3.11B), 
however it produced its own complications. During immunofluorescence, the collagen had 
been acting as a protective layer around the organoids, so its removal exposed the delicate 
structures to damage during the staining process. As a result of this, the morphology of the 
organoids was often compromised, and the structures did not remain intact (Fig. 3.11C). 
Disruption appears to be most severe in induced (KO) organoids, possibly due to their reduced 








Figure 3.11 | Confocal images showing organoids with and without collagen. A) Images of 
two organoids displaying fluorescence associated with E-cadherin (488-green), TdTomato 
(red) and DAPI (blue) to demonstrate the level of background fluorescence seen when 
organoids remain in collagen. B) Two uninduced (WT) organoids with a clear background due 
to additional collagenase step. C) Two induced (KO) organoids demonstrating the level of 















3.6 Ki67 Staining 
 
Next, an investigation was undertaken to determine what proportion of cells in the organoids 
were actively proliferating and whether or not they were in a specific distribution or localised 
in any part of the organoid. Immunofluorescence was carried out using a Ki67 antibody (594) 
along with an E-cadherin antibody (488) and DAPI on two plates (one induced (KO) and one 
uninduced (WT)), both on day 7 of culture. Organoids were then imaged using a confocal 
microscope (Fig. 3.12). 
 
From the confocal imaging, it can be observed that cells positive for Ki67 staining are dispersed 
throughout both the induced (KO) and uninduced (WT) organoids with no obvious patterning 
or localisation. Staining can be seen in both cells within the organoid and myofibroblast cells 
around the exterior of the main organoid body (Fig. 3.12B). Although it appears that Ki67 
positive cells in the induced organoid are predominantly E-cadherin negative, there are E-







Figure 3.12 | Ki67 staining in organoids showing proliferating cells. A) Confocal images 
of an uninduced (WT) organoid showing positive Ki67 staining (594-red) in several cells, along 
with E-cadherin staining (488-green) and DAPI (blue). Ki67 staining is visible both on the 
surface and in the centre of the organoid. B) confocal images of an induced (KO) organoid 
with positive Ki67 staining. Ki67 positive cells are randomly dispersed throughout the 








3.7 CD44 Staining 
 
As a last characterisation step, an investigation was carried out into CD44 expression in the 
organoids. As noted earlier, the Cre recombinase is under the CD44 promotor, and therefore 
every cell expressing CD44 in theory has the potential to activate TdTomato fluorescence. To 
assess this, immunofluorescence was carried out on one dish of induced organoids after 6 days 
of culture using a CD44 antibody (488-green) and DAPI. Organoids were then imaged using 
the confocal microscope. 
 
The CD44 staining for this experiment was not satisfactory due to poor antibody quality. 
Because of time restrictions, only one replicate was performed, and as a result there were no 
conclusive results. This is an experiment that will be optimised and repeated in future research. 
 
3.8 Concluding Remarks 
 
In summary, the optimisation phase of this project has provided powerful insight into the 
morphological characteristics and behaviours of our inducible E-cadherin knockout organoids. 
Although there are several important experiments still to be done, the results described above 
have provided enough of a foundation to confidently move forward into the drug screening 






Chapter 4: Optimisation Discussion 
 
Despite their inherent diversity, the growth patterns of the organoids were relatively consistent 
throughout all experiments. The growth pattern seen here reflected those observed in other 
models of a similar nature (Katano et al., 2015; Ootani et al., 2009), and although growth was 
not sustained beyond 20 days during this project, other groups have shown that it is possible to 
maintain organoid growth for as long as one year, though additional growth factors need to be 
supplemented into the media (Ootani et al., 2009). An investigation into the longevity of this 
specific HDGC organoid model is something that should be looked into in future research. This 
would provide important insight into the unique long-term growth patterns of the E-cadherin 
knockout organoids. For example, it has been shown that some organoid models are 
inconsistent in their growth rates, displaying alternating periods of rapid and slow growth over 
time (Ootani et al., 2009). Additionally, it would be of interest to look into how the composition 
of the different cell types change in the organoids over a prolonged period of time. For example, 
an investigation into whether some gastric cell types differentiate later in organoid 
development than others would be of value to the overall characterisation of the organoids. 
Another important research point would be to investigate whether long-term growth rate is 
determined by the size of the organoid’s stem cell population at any given time. Answering 
these questions would provide valuable insights for the development of this and other organoid 
models. 
 
When using the tissue from one mouse stomach per 35mm dish, anywhere between 5 and 20 
true organoids could be expected to grow in each dish. Despite adhering to a strict protocol, 
this variation in organoid numbers could not be eliminated. It is possible that the main factor 
determining organoid growth is the composition of cells in each segment of primary tissue. For 
 75 
the most part, this variation was mitigated by ensuring the tissue was minced the same amount 
for each experiment. However, it is not possible to control exactly what cell types are in each 
tissue segment and as a result some variation remains. Overall, this variation in organoid 
numbers did not pose any problems, apart from during drug testing when there was variation 
in organoid numbers both between replicates and in the different conditions within replicates.  
 
When imaging the organoids, it was imperative that the techniques provided accurate and 
detailed visualisation of the complex organoid structures. This was somewhat challenging, as 
the 3D structures vary significantly in morphology. Firstly, an imaging technique was needed 
to visualise the growth of the live organoids. For this, regular brightfield imaging allowed for 
recording the organoids in sufficient detail to give insight into their growth behaviours. Early 
on, it became obvious through brightfield imaging that the organoids follow a growth pattern 
that was consistent across experiments. However, brightfield imaging could not provide insight 
into other important aspects of the organoids. For one, their 3D spherical morphology is not 
visible in brightfield. This meant that from the brightfield images alone, it could not be 
concluded that the organoids were cystic and contained a lumen. Secondly, when experiments 
looking at induction of the Cdh1 knockout were to begin, the percentage of E-cadherin 
deficient cells would remain unknown after brightfield imaging. 
 
The latter issue was overcome with the use of immunofluorescence staining and fluorescent 
imaging. By staining the organoids with an E-cadherin antibody and DAPI, then visualising 
them on the inverted fluorescent microscope, visualisation of the approximate number of cells 
with and without Cdh1 expression was possible. This provided valuable insight into the relative 
success of our conditional knockout model. However, this technique was limited in that it still 
did not provide comprehensive information on the 3D morphology of the organoids. 
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Furthermore, it was limited in that the knockout could not be visualised in real-time, only as 
an endpoint analysis.  
 
Confocal microscopy utilises a small pinhole to concentrate a laser at specific and changeable 
depths in a sample, resulting in the production of high resolution images at different cross-
sections through a specimen. This allows for the visualisation of not only the outer surface of 
the organoid, but also the inner core and each layer of cells. With the use of a confocal, it was 
identified that the organoids were consistently cystic, containing a large lumen. By collating 
the multiple images taken at different depths in the organoid, it was also possible to visualise 
the organoid as a whole in great detail. This tool allowed for a much greater understanding of 
the organoids and their structure, adding extensively to both this specific objective as well as 
the wider project. However, confocal microscopy is both expensive and time consuming. 
Therefore, there is still a place for fluorescence microscopy in the workflow. The final 
sequence of imaging techniques for subsequent experiments was as follows: initial brightfield 
imaging to track organoid growth in real time, immunofluorescence and fluorescence 
microscopy to assess the quality of the staining and to establish which organoids would be 
most useful and representative for confocal imaging, and lastly confocal imaging of a selection 
of organoids from the sample for detailed visualisation. Together, these imaging techniques 
provided a comprehensive picture of the organoids for this project and provided an effective 
and efficient way to qualitatively assess the results of future experiments. 
 
The organoids used throughout this project were generated from mice harbouring conditional 
Cdh1 mutations. This system circumvents the issue of the embryonic lethal phenotype caused 
by a homozygous Cdh1 knockout. It provides temporal and spatial control of the knockout, so 
that later embryonic or adult phenotypes can be accessed (Guo, Yang, & Lobe, 2002). Upon 
initial visualisation of the organoids, it was apparent that the knockout efficiency had not been 
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100% and varied significantly between organoids. These findings were not unexpected, as this 
Cre-inducible knockout system has been shown to harbour high amounts of variation in its 
knockout efficacy (Leonhard et al., 2008; Mirantes et al., 2013). This could be due to various 
components of the system. For example, endoxifen may not be reaching every cell in the 
organoid structure. 
 
For 100% knockout, another method for inducing the mutation in the organoids would need to 
be adopted, such as a lentiviral system. However, 100% knockout is not necessarily the target 
for these organoids as a model for HDGC. CDH1 mutation carriers are born with a 
heterozygous loss of the gene, later gaining homozygous loss through somatic mechanisms 
such as epigenetic silencing. This homozygous loss only occurs in a small subset of gastric 
cells, leading to the initiation of signet ring cell carcinomas (Guilford et al., 2010). Therefore, 
the organoids retaining a population of CDH1 positive cells is an asset to their accuracy as a 
model for HDGC.  
 
After doing initial optimisation and characterisation using the conditional knockout mice for 
Cdh1, mice that harboured an additional endogenous TdTomato fluorescent protein were 
analysed. TdTomato is a highly photostable tandem dimer that omits strong red fluorescence 
at a wavelength of 581. This protein is under the CD44 promotor in the mice used for this 
project, and in theory should be exclusively expressed in cells which have also undergone Cdh1 
inactivation.  The addition of an endogenous fluorescent protein allows for the visualisation 
and tracing of cells in real-time under the fluorescence microscope, without having to fix the 
organoids and run immunofluorescence. 
 
An experiment was done to investigate whether or not there was a difference in percentage of 
knockout cells between organoids that were exposed to endoxifen continuously and those 
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exposed only for 48 hours before it was removed from the media (results not shown). Being 
able to remove the endoxifen from the media after 48 hours would be of benefit when it comes 
to drugging experiments later on, as ideally the organoids would not be exposed to endoxifen 
and the chosen drug simultaneously. From this investigation, it was concluded that the 
difference between knockout percentage of organoids exposed to endoxifen for 48 hours versus 
96 hours was not significant, and therefore for subsequent experiments, it was acceptable to 
remove the endoxifen from the media after 48 hours of initial exposure. 
 
When analysing confocal images of induced organoids, it was observed that many of these 
organoids contained an infiltration of TdTomato-expressing cells in their lumen. Further, E-
cadherin negative cells also pooled in the centre of induced non-tomato organoids. One 
possible mechanism to explain this observation is that the E-cadherin negative cells with 
compromised cell-cell adhesion capabilities struggle to remain in the epithelial wall of the 
organoid and are pushed into the lumen. Meanwhile, the E-cadherin positive cells proliferate 
and maintain the structure of the organoid by holding the majority in the outer surface of the 
cystic epithelial structure. It is also possible that E-cadherin negative cells are not only pushed 
into the centre of the organoid, but also out into the collagen. The cells are predominantly 
pushed into the lumen as this area is void of collagen, so will be the path of least resistance. 
 
It is unknown if the cells that are pushed into the organoid lumen are dead, dying or alive, 
however this would be an area of priority to look into in the future. If the cells are alive, this 
could mimic aspects of the tumour invasion process. On the other hand, the cells observed here 
could be dead or dying, which would explain their shedding into the lumen as a form of 
expulsion. This has been seen previously in gastric organoids, where high numbers of apoptotic 
cells were found in the inner lumen (Katano et al., 2013b). 
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Over all, the optimisation and characterisation of these organoids was both a challenging and 
informative process. An important direction for the future, is further investigation into different 
cell type markers. To gain a comprehensive understanding of these organoids, it is vital that 
their cell-type composition is known. To do this, markers for different gastric cell types – such 
as chief cells and parietal cells – should be used. Knowing what gastric cell types these 
organoids are comprised of, in what proportions and in what organisation, will elucidate further 
how accurate they are as a model for the in vivo gastric environment. In theory, they should 
harbour all the cell types present in a gastric gland, however it is unknown at what stage each 
cell type differentiates, or whether some do at all. Further characterisation should also be 
completed using additional techniques, such as classical histology. This would provide another 
perspective to the morphological analysis of the organoids, deepening our understanding of the 
model and the cells that comprise it.  
 
In terms of longevity, it has been observed that growth slows down significantly after 
approximately 7 days. Therefore, it would be interesting to use a gastric stem cell marker, such 
as LGR5 (Barker et al., 2010), to investigate whether or not growth rate correlates with the size 
of the stem cell population in the organoid at any given time. If organoids with larger stem cell 
populations are growing faster, then this would be an indicator that the longevity of this model 
could be increased by maintaining the stem cell niche more effectively. At present, the primary 
method of stem cell niche maintenance is through the endogenous growth factors secreted by 
the myofibroblast cells. It is possible that to enhance the stem cell niche and increase the 
longevity of the model the media could be supplemented with additional growth factors, such 
as WNT and R-Spondin. Other groups have shown that with the addition of growth factors to 
the media, organoids can be maintained for upwards of one year (Ootani et al., 2009). This will 
be of great use in future projects when investigating the long-term consequences of HDGC in 
the organoids – for example, do they eventually develop signet ring cells? 
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There are other areas that should be optimised in order to improve this model, such as 
determining whether the organoids can be cryopreserved and resurrected without impacting 
their growth. Another area worth investigating is passaging of the organoids. Although passage 
was attempted multiple times throughout this project, satisfactory results were not achieved, as 
previously observed by others with this ALI model (Li et al., 2014). Having successful passage 
of the organoids would allow for expansion of the number of organoids being generated 
without having to use additional mice. This will be of benefit to all areas of this project, 
especially drug screening. Our laboratory is currently establishing a submerged model for 
HDGC organoids, to potentially use as a passageable model for drug screening to increase 
throughput. Even with this development, the ALI model will still be vital to the lab and this 
wider project, as it is known to be the model with the most accurate reflection of the in vivo 
environment (Pastuła et al., 2016).  
 
The investigations that have been done into these organoids have provided valuable insight 
into their accuracy, usefulness and limitations as a model for HDGC, and enough of a 








The usefulness of organoids is not limited to expanding our understanding of cancer 
progression and disease profile on a cellular level. Organoids can be used as a medium-
throughput tool for drug screening – either in research to discover novel treatments or in a 
clinical setting as a tool for personalised medicine.  
 
Within the scope of this project, the intention is to use them as a tool to screen compounds with 
the hopes of identifying drugs that impart a synthetic lethal effect on the conditional Cdh1 
knockout organoids. Four drugs were screened in total, chosen due to their promising results 
in 2D cell line screening conducted in our laboratory.  
 
Qualitative and quantitative techniques were used to analyse the effectiveness of the drugs and 
determine whether or not they would be put forward into subsequent animal model screening. 
It was expected that drug screening in the organoids would not only provide insight into the 
effectiveness of the drugs, but also into the usefulness of the organoids as an intermediate 
screening step and model for HDGC cancer progression. 
 
 
5.1 DMSO tolerance  
 
 
Before drug testing could begin, an investigation into the tolerance threshold of organoids for 
DMSO was carried out. DMSO is a widely used drug solvent, which at high concentrations 
can have a toxic effect on cell cultures. In the 2D cell line drug screening done in our laboratory 
using MCF10A and NCI-N87 cells, 0.1% DMSO can be tolerated by the cells for a prolonged 
period of time. 
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For this experiment, four dishes of uninduced (WT) organoids were set up, each dish containing 
between 10-15 organoids. The four dishes were left to culture for 48 hours, and then exposed 
to four different concentrations of DMSO (0.2%, 0.1%, 0.05% and 0%) for 96 hours. Organoids 
were imaged in brightfield every 24 hours and observations recorded. It has been suggested 
that the DMSO tolerance threshold for other 3D cell cultures lies between 0.1% and 0.01% 
(Pal, Mamidi, Das, & Bhonde, 2012), so organoids were expected to have a similar result. 
 
When exposed to 0.2% DMSO, the organoids did not display any significant growth over 48h. 
In addition to this, the cells that were there before DMSO exposure displayed characteristics 
suggestive of death 48h after exposure, such as disintegration, darkening and flattening (Fig. 
5.1A). Organoids displayed these same traits when exposed to 0.1% DMSO (Fig. 5.1B), 
however they took slightly longer to take effect – 72 h versus 48 h at 0.2%. At 0.05% DMSO, 
no ‘death’ phenotypes were observed within the 96 h experiment timeframe (Fig. 5.1C). As a 
result, this concentration of DMSO was used in the future drug testing studies. Concentrations 













Figure 5.1 | DMSO tolerance screening in the organoids. A) Brightfield images of three 
organoids representative of the dish exposed to 0.2% DMSO on day 2 (0 hours post treatment) 
and day 4 (48 hours post treatment). Organoids have a darkened, flattened appearance and are 
beginning to disintegrate. B) Three organoids exposed to 0.1% DMSO for 96 hours. Also 
showing a darkened appearance on day 6. C) Three organoids exposed to 0.05% DMSO for 96 
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5.2 Drug Screening Protocol 
 
For drug screening, four dishes were used for each experiment with the tissue of one neonatal 
mouse stomach in each. Primary tissue was seeded in the collagen and complete media added 
to the surrounding dish. For the two plates intending to house induced (KO) organoids, 5 μM 
endoxifen was also added to the media. Organoids were left to grow without drug for 48 hours, 
after which the organoid media was changed, endoxifen removed and drug added to one 
induced (KO) dish and one uninduced (WT) dish and solvent control added to the remaining 
two dishes. After 6 days of total growth (4 days exposed to drug), organoids were fixed, stained 





Three replicates of the AKT inhibitor ARQ-092 were tested at a concentration of 5 μM using 
the protocol described above.  Notably, there was considerable variation between replicates in 
the number of organoids that grew in each dish, ranging from 5 to 20. 
 
The uninduced DMSO control organoids for this experiment displayed normal growth and no 
signs of death (Fig. 5.2A). They increased in size significantly between day 2 and day 6 and, 
on day 6, showed no signs of disintegration, flattening or substantial darkening. The induced 
DMSO controls (Fig. 5.2B) were comparable, exhibiting strong growth and no death 
phenotypes. The uninduced organoids exposed to ARQ-092 displayed relatively normal 
growth, although some, such as organoid 1, showed darkening on both days 2 and 6 (Fig. 5.2C). 
 
Induced organoids that were exposed to ARQ-092 for 96 hours exhibited distinct death 
phenotypes (Fig. 5.2D). By day 6, the organoids had lost their transparency, and were         
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instead comprised of darkened, grainy tissue. This darkening indicates necrotic cells, and the 
grainy texture along with the disrupted borders suggest that the organoids are beginning to lose 
























































Figure 5.2 | Representative brightfield images of organoids exposed to ARQ-092 and 
controls. A) Three uninduced (WT) DMSO control organoids on day 2 and day 6. Healthy 
growth and appearance has been maintained. B) Three induced (KO) DMSO control organoids 
on day 2 and day 6. Also exhibiting normal growth and no signs of death. C) Three uninduced 
(WT) organoids exposed to ARQ-092 on day 2 and day 6. Look relatively healthy after 6 days 
of growth. D) Three induced (KO) organoids exposed to ARQ-092 on day 2 and day 6. 
Displaying a reduced growth rate and phenotypes signifying death (textured, grainy appearance 
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Change in area has been used in this thesis as the primary quantitative measure of drug 
effectiveness. To measure this, the total area of each organoid was calculated on day 2 and day 
6, and the difference between the two calculated as a percentage change. By using percentage 
change, we were able to account for the high levels of variation in growth rate and starting size 
of the organoids. These values (from all three biological replicates) were then plotted on a line 
graph, where each line represents one organoid.  
 
Figure 5.3A shows that for ARQ-092, both the induced (KO) and uninduced (WT) DMSO 
controls displayed normal growth that increased at comparable rates, however the uninduced 
organoids exposed to ARQ-092 grew at a reduced rate, almost as low as that of the induced 
ARQ-092 organoids. When viewed on a smaller scale (Fig. 5.3B), there are a larger number of 
induced (KO) organoids displaying less than a 50% total increase in size. Furthermore, 17% 
(5) induced drug-treated organoids reduced in size, an effect not observed in the 


















Figure 5.3 | Percentage change in area of organoids from day 2-6. A) Each graph displays 
the collated data from three biological replicates. Individual lines represent the change in area 
of a singular organoid over the 96 hours of drug/DMSO exposure.  Uninduced (WT) and 
induced (KO) DMSO control organoids exhibit the highest rates of growth. Uninduced (WT) 
and induced (KO) organoids exposed to ARQ-092 display reduced growth. B) Close-up of 
percentage change in area for induced (KO) and uninduced (WT) graphs exposed to ARQ-092 
shows that KO/ARQ-092 organoids have a reduced growth rate compared to WT/ARQ-092 
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For each of the four conditions, the average percent change in area across all organoids was 
calculated and plotted on a bar graph (Fig. 9.3). Over 96 hours of treatment, uninduced (WT) 
organoids exposed to ARQ-092 have on average an 126% increase in size, whereas induced 
(KO) organoids show a 45% increase in size on average. This demonstrates a significant 
synthetic lethal effect (p=0.012). 
 
  
Figure 5.4 | Bar graph showing % Change in area of organoids exposed to ARQ-092 for 
96 h (Mean ± S.E). Graph displaying combined data for three biological replicates. Uninduced 
(WT)/ARQ-092 organoids (n=13) increase in area by 126% on average. Induced (KO)/ARQ-
092 organoids (n=30) increase in area by 45% on average, displaying a significantly reduced 
amount of growth (p=0.012). The uninduced (WT) (n=25) and induced (KO) (n=29) DMSO 
controls increase by 303% and 223%, respectively.  
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Confocal microscopy was used to capture more detailed images of the organoids and their 
morphology after drug screening. To do this, all four organoid dishes were fixed and stained 
with an E-cadherin antibody (488-green) and DAPI (blue) using the immunofluorescence 
protocol in section 2.8. The organoids were then examined using fluorescence microscopy and 
four organoids from each dish chosen for confocal imaging.  
 
Two DMSO control organoids (Fig. 5.5) are pictured below as a reference for changes to 
morphology induced by the drugs. Both the induced (KO) and uninduced (WT) DMSO control 
organoids displayed intact morphology with a spherical shape and regular cellular organisation. 
These images will be referred back to as DMSO control images for all confocal imaging from 
drug screening experiments as they are representative of the general morphology of DMSO 





Figure 5.5 | Confocal images of DMSO control organoids. Confocal imaging showing (A) 
uninduced (WT) and (B) induced (KO) DMSO control organoids displaying 
immunofluorescence associated with E-cadherin (488-green) and DAPI (blue). Red 
fluorescence in induced (KO) organoid is TdTomato. Both have intact structures and normal, 
spherical morphology. Dark patches on uninduced organoid are artefacts from the imaging 








Figure 5.6 shows confocal images of uninduced (WT) organoids that have been exposed to 
ARQ-092. Regardless of any growth inhibition that has taken place, the morphology of 
organoid 1 is largely normal. Its intact, regular morphology is comparable to the DMSO control 
seen in Figure 5.5. Organoid 2 is an abnormal shape, harbouring a doughnut-like hole in the 
centre. Although relatively rare, this shape does occasionally occur in normal organoids under 





Figure 5.6 | Confocal images of uninduced (WT) organoids exposed to ARQ-092. 
Organoids were stained with an E-cadherin (488-green) antibody and DAPI (blue) after 6 days 
of growth. The organoids pictured are positive for lattice-like E-cadherin staining localised to 
the adherens junctions and demonstrate intact structures with clear borders and organised cells. 
Organoid 2 has a doughnut-like shape, which although rare, can occur in normal organoids 
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Four induced organoids that were exposed to ARQ-092 for 96 hours are shown in Figure 5.7. 
The structure and organisation of all four organoids is highly disrupted, although to a variable 
extent.  Organoid 1 in this series is smaller and remains relatively undisrupted in its bottom 
half. However, the top segment of the organoid has begun to disintegrate, visible in the major 
disruption of the structure and displacement of cells out of the main organoid body. This 
disfigured section of the organoid is where the majority of the TdTomato-expressing E-
cadherin negative cells are localised, suggesting they are more susceptible to the effects of the 
drug.  
 
Organoid 2 is arguably displaying the most disrupted morphology of the four organoids. The 
structure is highly disorganised with no definitive boundaries and an abundance of cells being 
displaced from the body of the organoid. Amongst this disruption, there is a sheet of E-cadherin 
positive cells that have remained intact.  
 
Organoids 3 and 4 remain relatively intact after exposure to ARQ-092, although these 
organoids are displaying signs of disruption in comparison to the induced (KO) DMSO control 
in Figure 5.5. Their borders are less defined, indicating that cells are being dislodged from the 
main organoid body and disintegration is starting to occur. In organoid 3, once again disruption 

















Figure 5.7 | Confocal images of induced organoids exposed to ARQ-092. All four organoids 
have been exposed to ARQ-092 for 96 hours and stained with DAPI and an E-cadherin 
antibody (488-green). Endogenous TdTomato fluorescence (red) is also visible. They contain 
varying levels of E-cadherin negative cells (TdTomato expression) as well as varying levels of 
morphological disruption. The cystic structures have started to break down and cells are 
becoming disorganised and scattered around the exterior of the organoid – seen most severely 
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In summary, ARQ-092 has emerged as an effective drug for inhibiting growth and inducing 
death in the E-cadherin-negative organoids and shows promise as a chemopreventative 
treatment for HDGC. Future experiments will test ARQ-092 at a range of concentrations, and 









The next drug candidate tested was MK2206, another pan-AKT inhibitor that produced 
promising results in the prior 2D cell line screens. Three replicates of this experiment were 
carried out using the protocol described in section 2.9 at a concentration of 6.25 μM. Once 
again, there was considerable variation between the replicates in the number of organoids that 
grew in each dish, ranging from approximately 5-20. 
 
Both the uninduced (WT) and induced (KO) DMSO controls displayed healthy growth, as 
visible in the brightfield images in Figure 5.8A and 5.8B. On day 6, these organoids were 
considerably larger than on day 2, and had retained their healthy, transparent, intact 
phenotypes. Uninduced (WT) organoids that had been exposed to MK2206, shown in Figure 
5.8C, showed no obvious signs of death on day 6, 96 hours after initial drug exposure. In 
contrast, the brightfield images of the induced (KO) organoids that were exposed to MK2206 

























































Figure 5.8 | Representative brightfield images of organoids exposed to MK2206 and 
controls. A) Uninduced (WT) DMSO control organoids on day 2 and day 6. Healthy levels of 
growth are seen, and no death phenotypes occur. B) Induced (KO) DMSO control organoids 
on day 2 and day 6. Also exhibiting normal growth and no signs of death. C) Uninduced (WT) 
organoids exposed to MK2206 for 96 hours. Healthy appearance maintained after 6 days of 
growth. D) Induced (KO) organoids exposed to MK2206 for 96 hours. These organoids have 
a highly reduced growth rate and are displaying phenotypes signifying death. All three 
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The percentage change in organoid size from day 2 to day 6 is shown in Figure 5.9. Both the 
induced (KO) and uninduced (WT) DMSO controls displayed normal growth rates. 
Interestingly, induced (KO) DMSO control organoids grew at a slightly reduced rate in 
comparison to the uninduced (WT) DMSO control organoids. This is most likely to be due to 
the slower growth rate of E-cadherin-deficient cells, as observed in the isogenic MCF10A cell 
line (Chen et al., 2014).  
 
The uninduced (WT) organoids exposed to MK2206 appeared to grow at a slightly reduced 
rate, however the induced (KO) organoids exposed to MK2206 showed a striking reduction in 
















Figure 5.9 | Data showing the percentage change in area of organoids from day 2-6.  Each 
graph displays the collated data from three biological replicates. Individual lines represent the 
change in area of a singular organoid over the 96 hours of drug/DMSO exposure. Uninduced 
(WT) (A) and induced (KO) (B) DMSO control organoids exhibit the highest rates of growth. 
Uninduced (WT) organoids exposed to MK2206 (C) display slightly reduced growth. Induced 
(KO) organoids exposed to MK2206 (D) have a highly reduced growth rate compared to 
WT/MK2206 organoids (p=0.0005) – the maximum increase being 132% compared to 469% 
in uninduced (WT) MK2206 organoids.  
 
 
For each of the four conditions, the average percent change in area across all organoids was 
calculated and plotted on a bar graph (Fig. 5.10). Over 96 hours of treatment, uninduced (WT) 
organoids exposed to MK2206 have on average an 185% increase in size, whereas induced 
(KO) organoids show a 52% increase in size on average. This demonstrates a significant 







Figure 5.10 | Bar graph showing Change in area of organoids exposed to MK2206 for 96 
h (Mean ± S.E). Graph displaying combined data for three biological replicates. Uninduced 
(WT)/MK2206 (n=18) organoids increase in area by 185% on average. Induced (KO)/MK2206 
(n=22) organoids increase in area by 52% on average, displaying a significantly reduced 
amount of growth (p=0.0005). The uninduced (WT) (n=23) and induced (KO) DMSO (n=28) 
controls increase by 290% and 222%, respectively.  
 
Once again, confocal imaging was carried out in order to gain a more detailed picture of 
organoid morphology. The two dishes containing uninduced (WT) and induced (KO) organoids 
exposed to MK2206 were fixed and stained with an E-cadherin antibody (488-green) and DAPI 
(blue) using the immunofluorescence protocol in section 2.8. The organoids were then 
 101 
examined using fluorescence microscopy and four organoids from each dish chosen for 
confocal imaging, the cleanest of which are displayed below. 
 
The uninduced organoid treated with MK2206 looked relatively intact despite 96 hours of drug 
exposure (Fig 5.11). The E-cadherin staining (488-green) appeared faint around the outer edges 
of the organoid, however this is likely due to limitations with exposure times during imaging. 
Overall, this organoid appeared structurally intact with clean borders, suggesting that MK2206 






Figure 5.11 | Confocal image of an uninduced (WT) organoid exposed to MK2206. The 
organoid pictured has been stained with an E-cadherin antibody (488-green) and DAPI (blue) 
96 hours after drug treatment. The organoid has retained an intact structure with clear borders 






Induced (KO) organoids that were exposed to MK2206 displayed some morphological 
disruption (Fig. 5.12), however not to the same extent as the damage caused by ARQ-092 (Fig. 
5.7). These organoids were relatively intact, although there was a significant number of cells 
expelled from the main organoid body, especially in organoid 2. It should be noted that much 
of the debris surrounding the organoids in these images is from the primary tissue and other 
organoids in the dish, rather than debris from the organoids themselves. The E-cadherin 
positive cells are growing out of the organoids as nodules in both organoids, but more 






Figure 5.12 | Confocal images of induced organoids exposed to MK2206. Organoids 1 and 
2 have been stained with an E-cadherin antibody (488-green) and DAPI 96 hours after drug 
treatment. Endogenous TdTomato fluorescence is also visible (red). Some morphological 
disruption is present, however organoid borders have remained relatively intact. Patches of E-
cadherin positive cells are growing out of the organoids as nodules (white arrows), particularly 
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Overall, quantitative and qualitative analysis supports the possibility that MK2206 induces 






The third drug screened was Vorinostat, also known as suberanilohydroxamic acid (SAHA), a 
histone deacetylase (HDAC) inhibitor that showed evidence of E-cadherin-related synthetic 
lethality in the previous 2D cell line screening. Vorinostat has a history of use in psychiatry 
and neurology, however more recently it has been used in anticancer therapy (Bubna, 2015). 
 
For drug screening, Vorinostat was used at a concentration of 1.5 μM in the protocol described 
in section 2.9. Due to time restrictions, only one replicate of this experiment was able to be 
performed. There were between 5-15 organoids per dish for this experiment.  
 
The induced (KO) organoids that were exposed to Vorinostat (Fig. 5.13D) exhibited relatively 
normal growth and no death phenotypes. Their growth appeared to be comparable to that of 
the DMSO controls (Fig. 5.13A and 5.13B) and the uninduced organoids exposed to the drug 
(Fig. 5.13C). The tissue of induced (KO) organoids that have been exposed to Vorinostat is 
transparent, and the organoids have retained their 3D, spherical structure with no 
disintegration. This suggests that at this concentration (1.5μM), Vorinostat has not had a visible 


























































Figure 5.13 | Brightfield images of organoids exposed to Vorinostat and controls. A) 
Uninduced (WT) DMSO control organoids on day 2 and day 6. Organoids display healthy 
levels of growth and no death phenotypes. B) Induced (KO) DMSO control organoids on day 
2 and day 6. Also exhibit normal growth and no signs of death. C) Uninduced (WT) organoids 
exposed to Vorinostat on day 2 and day 6. Organoids have retained healthy phenotypes. D) 
Induced (KO) organoids exposed to Vorinostat on day 2 and day 6. These organoids also appear 
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The two dishes containing uninduced (WT) and induced (KO) organoids exposed to Vorinostat 
were fixed and stained with an E-cadherin antibody (488-green) and DAPI (blue) using the 
immunofluorescence protocol in section 2.8. The organoids were then examined using 
fluorescence microscopy and four organoids from each dish chosen for confocal imaging, the 
cleanest of which are pictured below. 
 
Confocal imaging of the uninduced (WT) organoid exposed to Vorinostat also showed no 
obvious signs of morphological disruption or death (Fig. 5.14). Induced (KO) organoids that 
have been exposed to Vorinostat (Fig. 5.15) harboured high levels of variation in both 
morphology and percentage of E-cadherin-negative cells. For example, organoids 2 and 4 have 
a significantly higher number of E-cadherin-positive cells in comparison to organoid 3. 




















Figure 5.14 | Confocal image of an uninduced (WT) organoid exposed to Vorinostat. The 
organoid was stained with an E-cadherin antibody (488-green) and DAPI (blue) after 96 hours 
of drug exposure. The structure of the organoid has remained intact, implying that Vorinostat 
has not had a significant impact on morphology. The borders of the organoid look slightly 












Figure 5.15 | Confocal images of induced organoids exposed to Vorinostat. All four 
organoids have been exposed to Vorinostat for 96 hours and stained with DAPI (blue) and an 
E-cadherin antibody (488-green). The general structure of the organoids is relatively intact, 
suggesting that Vorinostat has not induced any major morphological damage. All four 




















3 Organoid 4 
 109 
The organoids in Figure 5.15 all display high levels of elongated, mesenchymal-like 
TdTomato-expressing cells that are projecting out of the main organoid body. This 
phenomenon occurs relatively frequently, particularly, but not exclusively, in organoids 
exposed to drug. The biological basis of this effect is somewhat unknown, but it is suggestive 
of an outgrowth of mesenchymal-like cells from the organoid to aid in structural support and 
growth factor production  (Katano et al., 2013b; Ootani et al., 2009). 
 
These experiments have shown that at 1.5 μM, Vorinostat has no visible effect on both induced 
(KO) and uninduced (WT) organoids. Repetition of this experiment at a range of higher 
concentrations may provide a differential. If a clear differential can be achieved, Vorinostat 
will be passed on to animal models as a potential drug treatment for the chemoprevention of 
HDGC. Due to only one replicate being performed, which only generated a small number of 
organoids, quantitative analysis was not carried out on the Vorinostat-treated organoids. This 
















The final drug screened during this project was MBCD, a cholesterol sequestering agent used 
experimentally for lipid raft disruption (Larbi et al., 2004) that had shown promising results in 
our 2D screens. MBCD was screened using the protocol described in section 2.9 at a 
concentration of 5 mM. Unlike the three drugs screened previously, MBCD is reconstituted in 
water rather than DMSO. As with Vorinostat, only one replicate of MBCD was able to be 
carried out due to time restrictions. There were between 5-15 organoids generated per dish for 
this experiment. 
 
Both the induced and uninduced water controls displayed normal growth and little sign of 
consistent death phenotypes (Fig. 5.16A and 5.16B). By day 4 (48 hours after drug treatment), 
both the uninduced (WT) (Fig. 5.16C) and induced (KO) (Fig. 5.16D) organoids had begun to 
display death phenotypes. By day 6 in both conditions, these death phenotypes had increased 
in severity. The uninduced (WT) MCBD-treated organoids (Fig. 5.16C) showed a grainy, 
flattened appearance and have started to disintegrate. This was also observed in the induced 
(KO) MBCD-treated organoids (Fig. 5.16D), in addition to severe darkening, especially in 
organoid 1.  
 
Figure 5.16E, which directly compares both the induced (KO) and uninduced (WT) organoids 
on day 4, highlights the increased intensity of the darkened and grainy texture of the induced 
(KO) organoids at this timepoint. Although the uninduced (WT) organoids are starting to 
display death phenotypes on day 4, they still look relatively healthy in terms of their colour, 














































































































Figure 5.16 | Brightfield images of organoids exposed to MBCD and controls. A) 
Uninduced (WT) water control organoids display healthy levels of growth and no death 
phenotypes after 6 days of culture. B) Induced (KO) water control organoids also exhibit 
normal growth and no signs of death after 6 days of culture. C) Uninduced (WT) organoids 
exposed to MBCD have a flattened, grainy appearance after 6 days of culture, indicating 
degradation and death. D) Induced (KO) organoids exposed to MBCD also have a flattened, 
grainy and darkened appearance, signifying death. E) Comparison between the uninduced 
(WT) and induced (KO) organoids on day 4 shows that death occurs in the induced organoids 
slightly earlier than the uninduced organoids under the same conditions.  
 
 
All four dishes used in this experiment were fixed and stained with an E-cadherin antibody 
(488-green) and DAPI (blue) using the immunofluorescence protocol in section 2.8. The 
organoids were then examined using fluorescence microscopy and four organoids from each 
dish chosen for confocal imaging. Due to poor quality staining/imaging, only one organoid 
from both the induced (KO)/water and uninduced (WT)/MBCD condition are shown below, 





















Figure 5.17 shows an induced (KO) organoid from the water control dish. The structure of the 
organoid looks intact and the overall morphology is normal. Figure 5.18 and 5.19 show an 
uninduced (WT) organoid (Fig. 5.18) and two induced (KO) organoids (Fig. 5.19) that have 
been exposed to MBCD for 96 hours. The level of damage visible from the confocal images in 
both these conditions surpasses that of any other drug seen so far. The structural disruption is 
severe, and large numbers of cells can be seen surrounding the organoids, which are possibly 
a combination of mesenchymal-like cell projections and epithelial cells that are beginning to 







Figure 5.17 | Confocal image showing an induced (KO) water control organoid after 6 
days of growth. The organoid has been stained with an E-cadherin antibody (488-green) and 
DAPI (blue). TdTomato fluorescence is also visible (red). Morphology looks intact and 










Figure 5.18 | Confocal image of an uninduced (WT) organoid exposed to MBCD. The 
organoid has been stained with an E-cadherin antibody (488-green) and DAPI (blue) 96 hours 
after treatment with MBCD. Drug-induced damage has caused the organoid to lose its intact 














Figure 5.19 | Confocal imaging of induced (KO) organoids after being exposed to MBCD. 
The organoids have been stained with an E-cadherin antibody (488-green) and DAPI (blue) 
after 96 hours of exposure to MBCD. TdTomato fluorescence is also visible (red). Both 
organoids are exhibiting clear signs of death. There is intense morphological damage occurring, 
with TdTomato-expressing cells surrounding the exterior of the organoid in a disorganised 
manner, possibly indicating the organoid has started to degrade, expelling cells and debris from 
its core.  
 
 
These experiments have shown that at 5 mM, MBCD is highly toxic to both induced (KO) and 
uninduced (WT) organoids, however, there is a suggestion of a greater impact on induced (KO) 
organoids. Repetition of this experiment at a range of lower concentrations may provide a 
clearer differential. If a clear differential can be achieved, MBCD will be passed on to animal 
models as a potential drug treatment for the chemoprevention of HDGC. Due to only one 
replicate being performed, which only generated a small number of organoids, quantitative 
analysis was not carried out on the MBCD-treated organoids. This will be carried out once 






5.7 Concluding remarks 
 
Overall, the drug screening phase of this project has produced diverse and promising results. 
The two AKT inhibitors, ARQ-092 and MK2206, have proved to be effective at inducing 
morphological damage and growth inhibition that was more severe in the E-cadherin-null 
organoids. Both drugs, after closer examination of the optimal dose, will be passed on to animal 
model screening. Vorinostat and MBCD will be screened at a range of different concentrations 
in an attempt to demonstrate a synthetic lethal effect in this model. Ultimately, all four drugs 
have provided valuable insight into the organoids, highlighting their advantages, limitations 





Chapter 6: Drug screening Discussion 
 
Drug screening using the organoids has provided valuable insight into both the drug candidates 
themselves as well as the ALI organoids and their usefulness as a model for HDGC. Four drug 
candidates were screened in total, all chosen because of their promising results in 2D screens 
carried out in two isogenic cell lines with and without E-cadherin: MCF10A, an epithelial 
breast cell line, and NCI-N87, a gastric cancer cell line.  
 
The first drug, ARQ-092, is a pan-AKT inhibitor that inhibits all three AKT isoforms. It is 
currently involved in several clinical trials as a therapeutic drug for overgrowth disorders and 
cancers, including a phase 1 study for the overgrowth disorder, Proteus syndrome, and a phase 
1b study in combination with hormonal treatment for advanced endometrial cancer (Brown & 
Banerji, 2017). ARQ-092 suppresses the PI3K/AKT pathway by both binding AKT to prevent 
it from localising at the membrane and activating, and binding active AKT to directly inhibit 
its function (Yu et al., 2015).  
 
Brightfield and confocal imaging showed induced organoids that had been exposed to ARQ-
092 for 96 hours exhibited distinct death phenotypes, such as darkened, grainy tissue. Notably, 
confocal imaging revealed populations of E-cadherin positive cells within the organoids that 
had remained intact, suggesting they are less susceptible to the drug. Imaging, in conjunction 
with quantitative analysis, revealed that ARQ-092 was also having a growth inhibiting effect 
on uninduced organoids. However this effect, on average, is greater in the induced organoids 
(p=0.012), consistent with our prior 2D cell line data. 
 
Although the overall trend was for greater sensitivity of the induced organoids to the drug, 
there was considerable variability between organoids receiving the same treatment. Variation 
in drug response could be due to a multitude of contributing factors. For example, position of 
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the organoid in the collagen may have an impact on drug delivery and accessibility. 
Additionally, the exact cellular composition and relative numbers of each cell type in the 
organoid may have an impact on drug response. This will vary depending on the original cell 
population that generated the organoid. This could affect drug response as different gastric cell 
types could vary in their drug sensitivity. Another contributing factor to level of drug response 
will be the percentage of E-cadherin negative cells within the organoid. As discussed 
previously, the percentage of knockout cells can range anywhere between 50-90% in any given 
organoid. In theory, ARQ-092 should have a greater effect on E-cadherin negative cells. 
Therefore, the higher the percentage of E-cadherin negative cells in an organoid, the more 
pronounced the drug effect would be expected to be.  Once more repeat studies have been 
carried out, we will be able to test this possibility by correlating the level of TdTomato 
expression with the observed drug response. 
 
Overall, ARQ-092 has emerged as a promising drug candidate for the chemoprevention of 
HDGC. However, the observation that the uninduced (WT) organoids exposed to ARQ-092 
had a reduced growth rate in comparison to the DMSO control demonstrates that toxicity in 
healthy tissue will need to be reduced or managed.  As the PI3K/AKT pathway is involved in 
such integral cellular functions, such as cell growth, proliferation and survival signalling, it is 
not surprising that a drug inhibiting this pathway will have some toxicity and negative 
downstream effects, even in healthy cells with functional E-cadherin. Therefore, testing 
promising drugs, such as ARQ-092, at different concentrations will be an important future 
direction for this project. It is possible that the general toxicity of this drug might be greater in 
the organoids in comparison to the 2D cell lines previously tested, regardless of concentration. 
This variance highlights the importance of the organoids as a complementary model system for 
drug screening. 
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Although to our knowledge there has been no data yet published reporting screening results of 
ARQ-092 in organoids, promising results have been described in other models. Along with 
reports of strong antiproliferative activity in several cancer cell lines, ARQ-092 was shown to 
reduce tumour activity by 90% in xenograft models of endometrial cancer and show good 
activity in breast cancer (Yu et al., 2015).  Studies such as these, along with the work described 
here, suggest that this drug may prove to have valuable clinical utility. 
 
MK2206, also a pan-AKT inhibitor, was the second drug screened on the organoids.  It works 
by inhibiting both auto-phosphorylation of AKT, as well as AKT-mediated phosphorylation of 
downstream signalling molecules. It is currently involved in a number of phase 1 and phase 2 
clinical trials for a wide range of cancers and yielding promising results (Brown & Banerji, 
2017). 
 
Brightfield and confocal imaging of induced (KO) organoids exposed to MK2206 displayed a 
considerably reduced growth rate as well as morphological signs of death, including darkened 
and grainy tissue. This is in stark contrast to the uninduced (WT) organoids, which displayed 
normal growth and healthy tissue. These observations were backed up with quantitative data, 
which showed significantly reduced growth in the induced organoids (p=0.0005). This 
indicates that MK2206 is inducing death in a synthetic lethal manner – a finding that reflects 
the 2D cell line screens, further validating the organoids as a drug screening tool for HDGC. 
 
MK2206 is one of the most highly tested AKT inhibitors on the market and is yielding 
promising results. In one study that included  MK2206, intestinal organoid drug responses  
were  shown to accurately reflect the results of a parallel clinical trial, further validating their 
usefulness as a disease model (Vlachogiannis et al., 2018). MK2206 will likely continue to 
show therapeutic potential for various cancers in the future. 
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In summary, both AKT inhibitors, ARQ-092 and MK2206, produced a synthetic lethal effect 
in the organoids, although ARQ-092 was slightly more toxic. In future experiments, both drugs 
will be screened at a range of concentrations and in different combinations to find the optimum 
point for maximal synthetic lethality as well as minimal toxicity. Following this, the drugs will 
be put forward for screening in the animal models.  
 
The remaining two drugs that were screened, Vorinostat and MBCD, did not produce results 
as conclusive as the previous two. As this organoid model is relatively low throughput, drugs 
were only screened at one concentration initially. This concentration was chosen using the 
IC50 values from the 2D screen. Although the 2D screens can give a suitable concentration 
range, effective concentrations may not always translate between 2D and 3D screening models. 
This drawback was illustrated by the Vorinostat and MBCD studies which appeared to have 
been used at too low and too high concentrations respectively. 
 
Both these drugs will be screened at a range of concentrations to elucidate whether or not they 
have the ability to induce synthetic lethal death in the organoids. If successful, they will be 
passed on to animal models. Despite failing to validate the synthetic lethality of these drugs, 
they provided valuable insight into other aspects of the model, such as organoid-derived 
myofibroblast growth (discussed below) and the morphological changes that occur during 
organoid death – seen in the highly toxic effects of MBCD.  
 
Drug screening in organoids, both for drug discovery and as a pre-clinical tool for drug 
selection using patient derived organoids is increasing in popularity globally. Studies have 
shown that in drug discovery, organoids are closely reflecting the results of animal model 
screens and human trials (Jabs et al., 2017). Further, in drug selection, patient derived 
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organoids closely mirror patient response – as seen with metastatic gastrointestinal cancers 
(Vlachogiannis et al., 2018). The drugs screened as part of this project add to the ever-
expanding list of potential therapies for which organoids have contributed to the discovery and 
clinical application of, further emphasising their value in the field.   
 
Imaging throughout the various drugging experiments revealed that many of the organoids 
contained large amounts of elongated, TdTomato-expressing cell projections. This occurs to 
the largest extent in induced organoids under drugged conditions, as well as in induced DMSO 
controls and occasionally in uninduced organoids under drugged conditions. As these cells are 
expressing TdTomato in the induced organoids, they must be generated from the organoids 
themselves, rather than from the myofibroblast cells present in the collagen. This could be a 
sign of dysregulated asymmetric division of stem cells within the organoid, or cells gaining 
migratory potential, however neither option explains why the cells have a highly elongated 
phenotype or exist in uninduced organoids. The most likely explanation is that the organoids 
are projecting out mesenchymal-like cells, a process that occurs naturally in small numbers 
(Katano et al., 2013b; Ootani et al., 2009) but is enhanced under stress-inducing conditions 
such as drug or DMSO exposure (Lahar et al., 2011). The production of additional 
mesenchymal-like cells may reduce the impact of the environment by promoting regrowth of 
the epithelium and enhancing barrier function (McKaig, Makh, Hawkey, Podolsky, & Mahida, 
1999). 
 
The challenges faced during this phase of the project were numerous, and not all were 
overcome. The high levels of variation in organoid size and numbers made quantitative 
assessment difficult, however once the various ways of displaying the data had been 
established, this was for the most part overcome. A major challenge of this model, highlighted 
by the screening of Vorinostat and MBCD, is only being able to test one concentration at a 
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time. Due to the size of the dishes and the time restraints in mouse culling/tissue seeding, the 
amount of conditions per experiment is limited. This is somewhat problematic, however the 
initial concentration used will often be able to provide a good indication of what concentrations 
to test in the future. The submerged organoid model (Barker et al., 2010), currently under 
development in our laboratory, is higher throughput due to the dish size used, and therefore 
will be able to aid in solving this problem. However, the ALI model will still be needed in drug 
screening due to its higher accuracy in recapitulating the in vivo HDGC environment. A 
possible workflow will be to do initial screening using the submerged model of a range of 
concentrations for each drug before subsequently screening the most effective concentration 
on the ALI organoids as a final step before animal model screening.  
 
Another useful future experiment will be to do immunofluorescence using the proliferation 
marker Ki67 on organoids that have been exposed to growth-inhibiting drugs. Ki67 staining 
will allow for the visualisation of the differences in rates of cell proliferation between organoids 
that are displaying reduced growth rates and organoids that are growing normally, further 
validating the effects of the drugs. In addition to this, experiments using a live dead stain could 
be done as an additional quantitative measure of drug effectiveness alongside change in area. 
These future experiments will provide a more definitive answer on whether the drugs are 
inflicting primarily a cytostatic or cytotoxic effect. In addition to this, comparison of the E-
cadherin-positive and E-cadherin-negative areas within a single organoid, and how they 
respond to any given drug, is a potentially valuable area of future investigation. This 
comparison would control for potentially confounding variables between organoids, such as 
exposure to different drug concentrations due to their position in the collagen, which contains 




Chapter 7: Concluding remarks and Project Significance 
 
At the outset of this project, two main objectives were identified: firstly, to optimise culture 
techniques and characterise the conditional Cdh1 knockout organoids. Secondly, to use this 
model as a medium-throughput drug screening tool for the chemoprevention of HDGC. Over 
the duration of this project, many challenges arose, and not all were overcome. However, the 
insight gained from the various experiments has been of great value and clear pathways have 
emerged for future investigation.  
 
The characterisation and optimisation of the organoids taught us a lot about their growth, 
behaviour and morphology. The successful induction of the Cdh1 knockout validated the 
organoids as a model for HDGC and provided insight into how the organoids might 
demonstrate disease progression, such as with the pooling of E-cadherin negative cells in the 
lumen.  
 
As detailed in chapter 4, additional experiments will need to be carried out in the future in order 
to complete the characterisation of these organoids. Arguably, the most important of which is 
a thorough investigation into the gastric cell types present in the organoids and their 
organisation. This will aid in determining how accurate of a gastric model the organoids are. 
These experiments can be done using further fluorescent microscopy with various gastric cell 
type markers, as well as through histological techniques such as haematoxylin and eosin (H&E) 




The drug screening phase of this project yielded promising results, identifying two drug 
candidates (ARQ-092 and MK2206) with the ability to consistently display strong synthetic 
lethal effects in the conditional Cdh1 knockout organoids. Two more candidates (Vorinostat 
and MBCD) were also screened, but these drugs will require dose titrations before any 
conclusions on their potential utility can be made. In addition to this, the drug screening 
provided valuable insights into organoid death processes, DMSO tolerance and the various 
ways organoids react to stress, such as the proliferation of mesenchymal-like cells. 
 
As well as performing dose titrations, further work will be done to provide a more detailed 
assessment on the effects of the drugs screened throughout this project. These experiments will 
include both Ki67 staining and live/dead assays in order to elucidate whether the effects of the 
drugs are primarily cytostatic/growth inhibiting or cytotoxic/death inducing. Once this 
additional analysis has been done, drugs with a significant synthetic lethal effect will be 
forwarded on to animal models. 
 
This project has the potential to directly impact the care of over 500 HDGC families and 
thousands of CDH1 mutation carriers worldwide. Moreover, the knowledge gained will also 
be of potential use for research into treatments for sporadic DGC. As it stands, gastric cancer 
is consistently the second highest cause of cancer-related death worldwide (Nadauld & Ford, 
2013) and standard chemotherapies provide little benefit for DGC patients (Smalley et al., 
2012). The detrimental effects of gastric cancer are especially prominent in New Zealand, 
where our Māori and Pasifika populations harbour a 3-fold higher incidence compared to the 
global average (Ministry of Health, 2015). Therefore, there is an urgent domestic and 
international need for new drugs for the chemoprevention and treatment of the familial and 
sporadic forms of this disease. The work described in this thesis provides an exciting direction 
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A.1 Reagent preparations 
 
 
A.1.1 Antibody diluting buffer 
Antibody diluting buffer for immunofluorescence consisted of 10% FHS and 2% FBS in 
PBS. 
 
A.1.2 Blocking buffer 
Blocking buffer for immunofluorescence consisted of 10% FHS in PBS. 
 
A.1.3 Phosphate buffered saline (PBS) 
PBS was made by dissolving one PBS tablet per 100mL H20, then autoclaving to sterilise. 
 
A.1.4 Myofibroblast freezing medium 
Freezing medium for myofibroblast cells (MFB11) consisted of 80% complete culture media, 
10% additional FBS and 10% DMSO. 
 
A.1.5 Trypsin preparation 
0.05% trypsin was made by diluting 0.5% Trypsin at a 1:10 ratio with PBS. 
 
 
